https://trial.medpath.com/news/bayer-expands-genetic-medicine-portfolio-through-strategic-sirna-and-ai-partnerships 2026-01-08T01:44:27+00:00 hourly 0.9 https://trial.medpath.com/news/picard-medical-launches-fda-cleared-connector-covers-for-syncardia-total-artificial-heart 2026-01-08T01:44:21+00:00 hourly 0.9 https://trial.medpath.com/news/nucana-appoints-theresa-bruce-as-coo-to-advance-cancer-drug-pipeline 2026-01-08T01:43:39+00:00 hourly 0.9 https://trial.medpath.com/news/dem-biopharma-to-present-first-in-class-adc-dem301-for-gastrointestinal-cancers-at-asco-gi-2026 2026-01-08T01:43:37+00:00 hourly 0.9 https://trial.medpath.com/news/two-novel-parkinson-s-therapies-advance-to-late-stage-clinical-trials 2026-01-08T01:42:42+00:00 hourly 0.9 https://trial.medpath.com/news/instil-bio-terminates-licensing-agreement-and-discontinues-lead-cancer-drug-development 2026-01-08T01:41:58+00:00 hourly 0.9 https://trial.medpath.com/news/exvade-bioscience-enrolls-first-patients-in-revolutionary-glioblastoma-trial-using-fda-breakthrough-tumor-monorail-device 2026-01-08T01:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/sparrow-pharmaceuticals-initiates-phase-2b-trial-of-clofutriben-for-difficult-to-control-type-2-diabetes 2026-01-08T01:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/mdxhealth-partners-with-oxford-to-validate-genomic-prostate-score-in-landmark-protect-trial 2026-01-08T01:35:48+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-cuts-childhood-vaccine-schedule-from-17-to-11-diseases-impacting-major-vaccine-manufacturers 2026-01-08T01:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/novoron-bioscience-secures-2-5m-nih-grant-to-advance-human-brain-organoid-platform-for-alzheimer-s-drug-discovery 2026-01-08T01:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/legacy-healthcare-receives-fda-clearance-to-advance-botanical-drug-cinainu-into-phase-3-trial-for-alopecia-areata 2026-01-08T01:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/vivavision-biotech-receives-fda-approval-for-streamlined-vvn461hd-development-path-in-non-infectious-anterior-uveitis 2026-01-08T01:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/baird-medical-expands-global-microwave-ablation-technology-footprint-with-new-market-launches 2026-01-07T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/alloy-therapeutics-names-christian-cobaugh-ceo-of-genetic-medicines-division-to-advance-anticlastic-rna-platform 2026-01-07T09:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-s-gene-silencing-drugs-show-promise-in-early-obesity-studies-enhancing-weight-loss-when-combined-with-zepbound 2026-01-07T09:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/seres-therapeutics-publishes-mechanism-data-for-vowst-in-nature-medicine-validates-live-biotherapeutics-platform 2026-01-07T09:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/three-biotech-companies-secure-international-funding-for-next-generation-genetic-medicine-platform 2026-01-07T09:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-acquires-dark-blue-therapeutics-for-up-to-840-million-to-advance-acute-leukemia-pipeline 2026-01-07T09:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/roche-secures-patent-license-for-obesity-drug-ct-996-in-100-million-deal-with-structure-therapeutics 2026-01-07T09:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/3t-biosciences-strengthens-leadership-with-key-appointments-to-advance-solid-tumor-immunotherapy-pipeline 2026-01-07T09:30:26+00:00 hourly 0.9 https://trial.medpath.com/news/kincell-bio-appoints-industry-veteran-larry-pitcher-as-ceo-to-drive-cell-therapy-manufacturing-expansion 2026-01-07T09:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/aclaris-therapeutics-reports-positive-phase-1a-results-for-bispecific-antibody-ati-052-accelerating-development-timeline 2026-01-07T09:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/ibex-medical-analytics-expands-ai-powered-pathology-platform-to-support-early-stage-drug-development 2026-01-07T09:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/pridcor-therapeutics-advances-long-covid-treatment-with-peer-reviewed-publication-and-fda-ind-exemption-for-phase-2-shield-study 2026-01-07T09:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/bactolife-raises-eur30-million-series-b-to-commercialize-gut-health-binding-proteins-technology 2026-01-07T09:28:29+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-maviret-as-first-eight-week-treatment-for-acute-hepatitis-c 2026-01-07T09:28:03+00:00 hourly 0.9 https://trial.medpath.com/news/injectable-skin-derived-paste-shows-promise-for-breast-reconstruction-after-cancer-surgery 2026-01-07T09:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/eg-427-s-dna-therapy-eg110a-maintains-88-reduction-in-neurogenic-bladder-incontinence-at-24-weeks 2026-01-07T09:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-announces-ceo-succession-as-lisa-graver-takes-leadership-of-biosimilar-company 2026-01-07T09:27:47+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-nipocalimab-achieves-first-positive-phase-2-results-for-systemic-lupus-erythematosus-treatment 2026-01-07T09:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/genprex-s-gene-therapy-gpx-002-shows-promise-in-type-2-diabetes-animal-studies 2026-01-07T09:27:21+00:00 hourly 0.9 https://trial.medpath.com/news/stealth-biotherapeutics-advances-first-fda-approved-mitochondrial-therapy-forzinity-for-barth-syndrome 2026-01-07T09:27:21+00:00 hourly 0.9 https://trial.medpath.com/news/biomendics-advances-first-in-class-therapy-for-epidermolysis-bullosa-simplex-with-tames-02-trial 2026-01-07T09:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/zentalis-advances-azenosertib-toward-potential-accelerated-approval-with-key-2026-milestones-in-ovarian-cancer 2026-01-07T09:27:08+00:00 hourly 0.9 https://trial.medpath.com/news/galecto-strengthens-leadership-team-with-blueprint-medicines-veterans-as-dmr-001-advances-toward-clinical-trials 2026-01-07T09:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-partners-with-onconano-medicine-in-300m-drug-delivery-collaboration-for-cancer-therapeutics 2026-01-07T09:26:38+00:00 hourly 0.9 https://trial.medpath.com/news/vividion-s-wrn-inhibitor-vvd-214-shows-promise-for-msi-high-cancers-in-journal-of-medicinal-chemistry-publication 2026-01-07T09:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/bostongene-and-astrazeneca-partner-to-deploy-ai-foundation-model-for-precision-oncology-development 2026-01-07T09:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/regentis-gelrinc-demonstrates-near-complete-cartilage-repair-in-24-month-phase-ii-study-using-quantitative-mocart-assessment 2026-01-07T09:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/akebia-therapeutics-initiates-phase-2-trial-of-praliciguat-for-rare-kidney-disease-fsgs 2026-01-07T09:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/transcelerate-study-reveals-one-third-of-clinical-trial-procedures-are-non-essential-proposes-streamlined-data-collection-framework 2026-01-07T09:26:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-venous-stent-for-deep-venous-disease-in-ivc-and-iliofemoral-veins 2026-01-07T09:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/loqus23-advances-first-in-class-oral-drug-lqt-23-for-huntington-s-disease-treatment 2026-01-07T09:26:18+00:00 hourly 0.9 https://trial.medpath.com/news/billiontoone-s-northstar-select-liquid-biopsy-selected-for-major-japanese-lung-cancer-resistance-study 2026-01-07T09:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-acquires-dark-blue-therapeutics-for-840-million-to-advance-aml-treatment 2026-01-07T09:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/uk-italy-consortium-launches-ps3m-study-to-define-true-remission-in-inflammatory-arthritis 2026-01-07T09:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/variant-bio-launches-world-s-first-agentic-ai-platform-for-genomic-drug-discovery 2026-01-07T09:25:29+00:00 hourly 0.9 https://trial.medpath.com/news/iavi-initiates-phase-1-trial-of-novel-mrna-hiv-vaccine-targeting-broadly-neutralizing-antibodies 2026-01-07T09:25:26+00:00 hourly 0.9 https://trial.medpath.com/news/nanomosaic-appoints-dr-anne-marie-morse-to-lead-clinical-advisory-board-for-ultra-sensitive-diagnostic-platform 2026-01-07T09:24:56+00:00 hourly 0.9 https://trial.medpath.com/news/biosplice-submits-first-potential-disease-modifying-osteoarthritis-drug-to-fda 2026-01-07T09:24:12+00:00 hourly 0.9 https://trial.medpath.com/news/aclarion-advances-clarity-trial-enrollment-with-northwestern-medicine-and-scripps-health-participation 2026-01-07T09:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/apogee-s-zumilokibart-shows-promising-results-in-phase-1b-asthma-trial-with-durable-biomarker-suppression 2026-01-07T09:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/cyclerion-therapeutics-partners-with-medsteer-to-advance-cyc-126-for-treatment-resistant-depression 2026-01-07T09:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/leon-s-fr-jet-technology-enables-high-concentration-mrna-lnp-manufacturing-with-enhanced-in-vivo-activity 2026-01-07T09:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-initiates-european-enrollment-for-fortify-trial-testing-orticumab-in-post-heart-attack-inflammation 2026-01-07T09:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/hummingbird-bioscience-doses-first-patient-in-phase-i-trial-of-her3-targeted-adc-hmbd-501 2026-01-07T09:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/acesion-pharma-initiates-phase-2-trial-of-first-in-class-sk-ion-channel-inhibitor-ap31969-for-atrial-fibrillation 2026-01-07T09:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/ikarovec-secures-exclusive-option-for-vectorbuilder-s-novel-aav-capsid-technology-in-1b-deal-for-amd-gene-therapy 2026-01-07T09:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/gccl-expands-global-clinical-trial-network-through-strategic-partnerships-with-opis-and-medicover 2026-01-07T06:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/saga-diagnostics-expands-ultrasensitive-pathlight-mrd-test-to-colorectal-cancer-following-strong-citcca-study-results 2026-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/waters-corporation-shareholders-approve-17-5-billion-merger-with-bd-biosciences-transaction-set-to-close-february-2026 2026-01-06T17:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-azstarys-for-adhd-treatment-offering-first-dual-mechanism-therapy-for-23-million-affected-patients 2026-01-06T10:00:34+00:00 hourly 0.9 https://trial.medpath.com/news/bright-minds-biosciences-set-to-release-phase-2-results-for-bmb-101-in-drug-resistant-epilepsy 2026-01-06T10:00:32+00:00 hourly 0.9 https://trial.medpath.com/news/transpire-bio-achieves-first-human-dosing-milestone-for-novel-cns-inhalation-therapy 2026-01-06T07:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/gut-bacteria-derived-molecule-doubles-lung-cancer-immunotherapy-response-in-preclinical-study 2026-01-06T05:00:30+00:00 hourly 0.9 https://trial.medpath.com/news/sisram-medical-s-daxxify-clears-final-regulatory-hurdle-for-china-market-launch 2026-01-06T03:19:29+00:00 hourly 0.9 https://trial.medpath.com/news/alumis-to-report-phase-3-onward-topline-data-for-envudeucitinib-in-moderate-to-severe-plaque-psoriasis 2026-01-06T03:19:28+00:00 hourly 0.9 https://trial.medpath.com/news/in-vivo-car-t-therapy-gains-momentum-with-four-new-clinical-programs-entering-phase-1-studies 2026-01-06T00:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-raises-700-million-to-advance-rnai-therapeutics-pipeline 2026-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/indiana-attorney-general-sues-eli-lilly-over-alleged-insulin-price-manipulation 2026-01-05T21:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/decipher-genomic-classifier-shows-promise-for-predicting-prostate-cancer-treatment-outcomes 2026-01-05T21:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-reports-strong-q4-revenue-growth-of-28-driven-by-jakafi-and-opzelura-performance 2026-01-05T21:18:59+00:00 hourly 0.9 https://trial.medpath.com/news/genelux-reports-promising-early-results-for-olvi-vec-in-advanced-lung-cancer-trials 2026-01-05T20:19:26+00:00 hourly 0.9 https://trial.medpath.com/news/cornell-developed-silica-nanoparticles-transform-cold-tumors-to-enhance-immunotherapy-response 2026-01-05T20:16:48+00:00 hourly 0.9 https://trial.medpath.com/news/halozyme-expands-enhanze-technology-through-strategic-partnerships-with-takeda-and-skye-bioscience 2026-01-05T17:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/nrx-pharmaceuticals-and-neurocare-group-partner-to-create-nationwide-neuroplastic-therapy-network-for-depression-and-ptsd 2026-01-05T17:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/neumora-s-nmra-511-shows-clinically-meaningful-results-in-phase-1b-alzheimer-s-agitation-study 2026-01-05T17:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/tango-therapeutics-names-new-ceo-as-vopimetostat-advances-to-pivotal-studies 2026-01-05T17:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/coherus-oncology-publishes-promising-data-on-ccr8-targeting-antibody-tagmokitug-for-solid-tumors 2026-01-05T17:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-analysis-identifies-two-new-multiple-sclerosis-subtypes-advancing-precision-medicine-approaches 2026-01-05T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/major-leucovorin-autism-study-retracted-due-to-data-issues-as-largest-trial-approaches-2026-results 2026-01-05T17:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/multi-antigen-t-cell-therapy-shows-84-6-disease-control-rate-in-pancreatic-cancer-phase-1-2-trial 2026-01-05T17:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/okyo-pharma-appoints-ophthalmology-veteran-robert-dempsey-as-ceo-to-advance-neuropathic-corneal-pain-treatment 2026-01-05T17:20:53+00:00 hourly 0.9 https://trial.medpath.com/news/soleno-therapeutics-publishes-pivotal-vykat-xr-study-results-in-leading-endocrinology-journal 2026-01-05T17:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/civicascript-launches-low-cost-insulin-biosimilar-and-ustekinumab-alternative-in-us-market 2026-01-05T17:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/neumora-therapeutics-outlines-2026-pipeline-strategy-with-multiple-clinical-readouts-expected 2026-01-05T17:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/nanoscope-therapeutics-advances-optogenetic-therapy-with-rolling-bla-submission-and-expansion-plans 2026-01-05T17:20:42+00:00 hourly 0.9 https://trial.medpath.com/news/compass-therapeutics-strengthens-leadership-team-with-experienced-oncology-executives 2026-01-05T17:20:36+00:00 hourly 0.9 https://trial.medpath.com/news/nanjing-delova-s-qp-6211-achieves-primary-endpoints-in-phase-3-trials-for-postoperative-pain-management 2026-01-05T17:19:42+00:00 hourly 0.9 https://trial.medpath.com/news/bd-achieves-first-prophylactic-hernia-prevention-case-in-europe-with-phasix-mesh-as-prevent-trial-nears-completion 2026-01-05T17:19:37+00:00 hourly 0.9 https://trial.medpath.com/news/three-novel-anxiety-medications-advance-toward-2026-fda-review-marking-first-major-breakthrough-in-over-a-decade 2026-01-05T17:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-advances-rhb-102-for-glp-1-therapy-side-effects-as-market-faces-35-billion-loss-risk 2026-01-05T16:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/angitia-biopharmaceuticals-completes-enrollment-in-phase-2-trial-of-dual-target-osteoporosis-therapy-aga2118 2026-01-05T16:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-and-fast-track-designations-to-protara-s-tara-002-for-pediatric-lymphatic-malformations 2026-01-05T16:20:08+00:00 hourly 0.9 https://trial.medpath.com/news/gyre-therapeutics-secures-conditional-approval-pathway-for-hydronidone-in-china-following-successful-phase-3-trial 2026-01-05T16:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/maplight-therapeutics-receives-fda-fast-track-designation-for-alzheimer-s-disease-psychosis-treatment 2026-01-05T16:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-analysis-reveals-1221-precision-medicine-deals-worth-billions-since-2019 2026-01-05T16:19:11+00:00 hourly 0.9 https://trial.medpath.com/news/stimlabs-launches-first-fda-cleared-human-umbilical-cord-particulate-device-for-wound-management 2026-01-05T16:18:52+00:00 hourly 0.9 https://trial.medpath.com/news/synusight-abli-therapeutics-and-xingimaging-partner-to-advance-alpha-synuclein-pet-imaging-in-parkinson-s-disease-trials 2026-01-05T16:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/metavia-s-da-1726-demonstrates-9-1-weight-loss-and-significant-metabolic-benefits-in-phase-1b-obesity-trial 2026-01-05T16:18:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-generic-pergolide-tablets-for-equine-cushing-disease-treatment 2026-01-05T16:18:19+00:00 hourly 0.9 https://trial.medpath.com/news/jade-biosciences-advances-three-monoclonal-antibody-programs-for-autoimmune-diseases-with-phase-1-data-expected-in-2026 2026-01-05T13:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/argenx-announces-leadership-transition-as-karen-massey-set-to-replace-tim-van-hauwermeiren-as-ceo 2026-01-05T13:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/compass-therapeutics-advances-multiple-bispecific-antibody-programs-with-key-biliary-tract-cancer-data-expected-q1-2026 2026-01-05T13:18:09+00:00 hourly 0.9 https://trial.medpath.com/news/oral-htt-lowering-drug-branaplam-shows-promise-but-halted-due-to-peripheral-neuropathy-in-phase-2-huntington-s-disease-trial 2026-01-05T13:18:02+00:00 hourly 0.9 https://trial.medpath.com/news/megestrol-acetate-shows-dual-benefits-in-er-positive-breast-cancer-treatment 2026-01-05T13:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/earendil-labs-partners-with-sanofi-in-2-56-billion-ai-driven-bispecific-antibody-collaboration-for-autoimmune-diseases 2026-01-05T13:17:06+00:00 hourly 0.9 https://trial.medpath.com/news/alcanza-clinical-research-expands-network-through-strategic-acquisition-of-tampa-bay-medical-research 2026-01-05T12:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/scinopharm-becomes-first-taiwan-company-to-win-fda-approval-for-complex-multiple-sclerosis-treatment 2026-01-05T09:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-s-bi-1808-plus-pembrolizumab-shows-24-response-rate-in-recurrent-ovarian-cancer 2026-01-05T08:41:54+00:00 hourly 0.9 https://trial.medpath.com/news/kaist-develops-ai-platform-for-b-cell-reactive-cancer-vaccines-plans-2027-clinical-trials 2026-01-05T08:41:34+00:00 hourly 0.9 https://trial.medpath.com/news/geneditbio-receives-fda-clearance-for-first-in-class-crispr-gene-therapy-trial-in-tgfbi-corneal-dystrophy 2026-01-05T08:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/orum-therapeutics-appoints-chad-may-as-chief-scientific-officer-to-advance-degrader-antibody-conjugate-platform 2026-01-05T06:39:21+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-shows-promise-for-rejuvenating-aging-intestines-in-preclinical-study 2026-01-05T06:39:03+00:00 hourly 0.9 https://trial.medpath.com/news/stereotactic-body-radiotherapy-shows-promise-for-oligometastatic-cancer-treatment-without-systemic-therapy 2026-01-05T06:36:59+00:00 hourly 0.9 https://trial.medpath.com/news/datasea-partners-with-chinese-bci-company-to-advance-acoustic-enhanced-brain-computer-interface-technology 2026-01-04T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/south-korean-biopharma-sector-gains-global-momentum-with-4-2-billion-in-licensing-deals 2026-01-04T13:25:40+00:00 hourly 0.9 https://trial.medpath.com/news/novel-microneedle-patch-combines-zerumbone-and-icg-for-dual-mode-melanoma-therapy 2026-01-04T13:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/beaver-trial-demonstrates-efficacy-of-binimetinib-encorafenib-combination-in-advanced-non-v600e-braf-mutated-tumors 2026-01-04T09:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/novel-cancer-vaccine-using-blood-cleaning-technology-enters-phase-1-trial-for-ovarian-cancer 2026-01-04T06:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/plant-derived-extracellular-vesicles-enable-itraconazole-delivery-across-blood-brain-barrier-for-glioblastoma-treatment 2026-01-04T05:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/neuralink-expands-human-trials-to-21-participants-as-musk-announces-next-generation-brain-implant 2026-01-04T04:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/lipid-nanoparticles-enable-durable-crispr-gene-editing-in-muscle-stem-cells-for-duchenne-muscular-dystrophy 2026-01-04T01:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-2-trial-demonstrates-safety-and-efficacy-of-autologous-cd133-stem-cell-therapy-for-asherman-syndrome 2026-01-03T22:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-brainspace-s-intellidrop-automated-brain-fluid-management-system 2026-01-03T20:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/live-tumor-fragment-platform-enables-real-time-assessment-of-immunotherapy-responses-in-cancer-patients 2026-01-03T18:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/genotype-guided-warfarin-dosing-reduces-dose-adjustments-in-asian-patients-across-multiple-subgroups 2026-01-03T12:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-expedited-marketing-authorization-for-altria-s-on-plus-nicotine-pouches 2026-01-03T08:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-therapeutics-submits-clinical-trial-application-for-srp-1005-huntington-s-disease-treatment 2026-01-03T03:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/gh-research-to-update-fda-ind-status-for-novel-mebufotenin-therapy-gh001-in-treatment-resistant-depression 2026-01-03T01:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/dcc-3009-phase-1-2-trial-targets-resistance-mutations-in-advanced-gist-patients 2026-01-02T21:25:50+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-reveals-optimal-androgen-deprivation-therapy-duration-for-localized-prostate-cancer-treatment 2026-01-02T21:24:42+00:00 hourly 0.9 https://trial.medpath.com/news/gabapentin-trial-aims-to-replace-opioids-for-cancer-treatment-related-mucositis-pain 2026-01-02T20:24:47+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-shows-promise-for-alcohol-use-disorder-treatment-in-emerging-research 2026-01-02T20:24:38+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-approves-zapomeran-kostaive-first-self-amplifying-mrna-covid-19-vaccine-for-adults 2026-01-02T17:25:30+00:00 hourly 0.9 https://trial.medpath.com/news/cdt-equity-partners-with-njs-foresight-bio-advisory-to-accelerate-solid-form-patent-out-licensing 2026-01-02T17:25:28+00:00 hourly 0.9 https://trial.medpath.com/news/genelux-appoints-dr-jason-litten-as-chief-medical-officer-to-advance-oncolytic-immunotherapy-olvi-vec 2026-01-02T17:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/gubra-expands-facilities-by-70-to-support-growing-peptide-drug-pipeline-and-cro-operations 2026-01-02T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-bacteria-burden-emerges-as-key-predictor-of-immunotherapy-resistance-in-head-and-neck-cancer 2026-01-02T12:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-padcev-shows-strong-phase-3-results-in-bladder-cancer-validating-43-billion-seagen-acquisition 2026-01-02T09:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/neovii-pharmaceuticals-appoints-frederic-prince-as-new-ceo-following-christian-loss-s-retirement 2026-01-02T08:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/adalta-secures-exclusive-global-rights-to-novel-car-t-therapy-bzds1901-for-mesothelioma-treatment 2026-01-02T05:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/ai-designed-drug-discovery-reaches-3-billion-milestone-as-isomorphic-labs-partners-with-eli-lilly-and-novartis 2026-01-02T01:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-launches-phase-4-study-testing-switch-from-tafamidis-to-acoramidis-in-attr-cm-patients 2026-01-02T01:23:54+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-combined-with-hormone-therapy-shows-35-greater-weight-loss-in-postmenopausal-women 2026-01-01T23:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-patient-achieves-transfusion-independence-following-crispr-gene-therapy-for-beta-thalassaemia 2026-01-01T21:27:07+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-upholds-helsinn-s-anti-nausea-drug-patent-dismisses-zydus-challenge 2026-01-01T18:24:31+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-subsidiary-acquires-khandelwal-labs-non-oncology-portfolio-for-325-crore 2026-01-01T17:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/xortx-highlights-breakthrough-genetic-research-doubling-known-gout-risk-factors-to-410 2026-01-01T16:25:07+00:00 hourly 0.9 https://trial.medpath.com/news/immunoforge-seeks-global-partners-for-fda-cleared-rare-disease-therapies-at-jpm-2026 2026-01-01T09:24:43+00:00 hourly 0.9 https://trial.medpath.com/news/bioengineered-viruses-enable-precise-rna-editing-in-macrophages-to-combat-sepsis 2026-01-01T04:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/axsome-therapeutics-receives-fda-priority-review-for-axs-05-in-alzheimer-s-disease-agitation 2026-01-01T02:26:08+00:00 hourly 0.9 https://trial.medpath.com/news/replimune-stock-surges-131-following-fda-acceptance-of-resubmitted-rp1-application-for-advanced-melanoma 2026-01-01T02:25:31+00:00 hourly 0.9 https://trial.medpath.com/news/next-day-hiv-viral-load-testing-fails-to-improve-treatment-uptake-in-clinical-trial 2026-01-01T00:28:10+00:00 hourly 0.9 https://trial.medpath.com/news/intelligent-bio-solutions-secures-strategic-manufacturing-partnership-to-cut-production-costs-by-40 2025-12-31T23:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/brazil-modernizes-drug-pricing-framework-with-new-cmed-regulation-effective-april-2026 2025-12-31T22:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-secures-1-1b-deal-for-zelgen-s-dll3-targeting-cancer-therapy 2025-12-31T21:26:54+00:00 hourly 0.9 https://trial.medpath.com/news/elanco-receives-usda-approval-for-befrena-anti-il31-monoclonal-antibody-for-canine-dermatitis 2025-12-31T20:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharmaceutical-patent-trials-set-for-2026-include-wegovy-and-covid-19-vaccine-technologies 2025-12-31T17:25:31+00:00 hourly 0.9 https://trial.medpath.com/news/emmaus-life-sciences-grants-exclusive-north-american-rights-for-sickle-cell-drug-endari-to-neoimmunetech 2025-12-31T17:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/xlife-sciences-partners-twelve-biotech-companies-with-grupo-landsteiner-plans-nasdaq-listing-for-2026 2025-12-31T16:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/bioatla-secures-40-million-funding-to-advance-ozuriftamab-vedotin-into-phase-3-trial-for-oropharyngeal-cancer 2025-12-31T16:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/six-year-evolut-low-risk-data-shows-higher-reintervention-rates-for-tavr-vs-surgery-in-low-risk-aortic-stenosis-patients 2025-12-31T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/male-contraceptive-pill-yct-529-completes-first-human-safety-trial 2025-12-31T13:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/wockhardt-files-european-marketing-application-for-novel-antibiotic-wck-5222-to-combat-drug-resistant-infections 2025-12-31T12:24:43+00:00 hourly 0.9 https://trial.medpath.com/news/co-diagnostics-secures-first-patent-for-point-of-care-pcr-platform-in-australia 2025-12-31T09:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-inotuzumab-ozogamicin-achieves-57-remission-rate-in-relapsed-refractory-b-all-despite-dose-modifications 2025-12-31T09:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/capsovision-submits-fda-application-for-ai-enhanced-capsule-endoscopy-system 2025-12-31T08:24:37+00:00 hourly 0.9 https://trial.medpath.com/news/arovella-submits-ind-application-for-first-in-human-trial-of-car-inkt-cell-therapy-ala-101 2025-12-31T05:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/maryland-pdab-sets-first-upper-payment-limits-for-diabetes-drugs-as-state-level-price-control-model-gains-momentum 2025-12-31T02:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/rhythm-pharmaceuticals-faces-fda-delay-for-setmelanotide-in-hypothalamic-obesity-as-stock-retreats-from-2025-highs 2025-12-31T01:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/two-autophagy-targeting-biotech-companies-advance-neurodegeneration-therapies-to-human-trials 2025-12-31T01:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/ultragenyx-completes-bla-submission-for-first-gene-therapy-targeting-glycogen-storage-disease-type-ia 2025-12-31T00:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/sinopia-biosciences-secures-nih-grant-to-advance-ai-powered-drug-discovery-platform 2025-12-30T19:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/neurothera-labs-secures-israeli-patent-for-novel-opioid-pea-combination-to-reduce-side-effects 2025-12-30T18:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/imunon-secures-7-million-in-registered-direct-offering-to-advance-phase-3-dna-mediated-immunotherapy 2025-12-30T17:26:49+00:00 hourly 0.9 https://trial.medpath.com/news/weizmann-institute-develops-novel-immunotherapy-strategy-targeting-drug-resistant-cancer-mutations 2025-12-30T17:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/inflarx-reports-encouraging-post-hoc-analyses-for-vilobelimab-in-pyoderma-gangrenosum-despite-phase-3-trial-termination 2025-12-30T16:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/uni-bio-science-forms-strategic-alliance-to-advance-growth-factor-combination-therapies-in-regenerative-medicine 2025-12-30T16:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/derazantinib-enhances-gemcitabine-efficacy-in-pancreatic-cancer-by-suppressing-nf-kb-and-mapk-pathways 2025-12-30T13:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-advances-triple-combination-cancer-therapy-with-nmpa-approval-for-hlx43-adc-study 2025-12-30T13:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-weight-loss-drugs-show-promise-for-addiction-treatment-in-early-clinical-studies 2025-12-30T09:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/royalty-pharma-acquires-full-evrysdi-royalty-rights-for-240-million-securing-100-interest-in-leading-sma-treatment 2025-12-30T06:26:23+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-blocks-hhs-340b-drug-rebate-pilot-program-protecting-hospital-discount-system 2025-12-30T03:47:10+00:00 hourly 0.9 https://trial.medpath.com/news/subgroup-analysis-of-phase-3-focus-study-reveals-optimal-patient-selection-for-melphalan-hepatic-delivery-system-in-uveal-melanoma 2025-12-30T03:26:48+00:00 hourly 0.9 https://trial.medpath.com/news/verastem-discontinues-kras-g12c-trial-to-focus-on-promising-g12d-inhibitor-with-69-response-rate 2025-12-30T03:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/traditional-chinese-herbal-formula-shows-superior-kidney-function-preservation-in-diabetic-kidney-disease-trial 2025-12-29T23:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/bluejay-diagnostics-completes-commercial-scale-il-6-antibody-production-for-sepsis-diagnostic-platform 2025-12-29T23:28:36+00:00 hourly 0.9 https://trial.medpath.com/news/imunon-reports-strong-phase-3-ovation-3-enrollment-progress-as-imnn-001-shows-promise-in-advanced-ovarian-cancer-treatment 2025-12-29T23:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/work-medical-receives-regulatory-approval-for-ai-powered-blood-cell-morphology-analyzer 2025-12-29T23:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/oncodesign-precision-medicine-and-navigo-proteins-terminate-radiotheranostics-collaboration 2025-12-29T23:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/ohsu-researchers-discover-breast-cancer-drug-palbociclib-overcomes-venetoclax-resistance-in-acute-myeloid-leukemia 2025-12-29T22:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/ultragenyx-s-setrusumab-fails-two-phase-3-trials-for-rare-bone-disease-shares-plummet-43 2025-12-29T22:24:32+00:00 hourly 0.9 https://trial.medpath.com/news/conavi-medical-submits-next-generation-hybrid-imaging-system-to-fda-as-clinical-guidelines-support-intravascular-imaging 2025-12-29T19:42:11+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-secures-exclusive-rights-to-novel-fortnightly-glp-1-receptor-agonist-bofanglutide-for-indian-market 2025-12-29T19:41:23+00:00 hourly 0.9 https://trial.medpath.com/news/cbih-pursues-patent-for-cannabinoid-based-therapy-targeting-opioid-addiction-recovery 2025-12-29T19:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/lund-university-researchers-identify-statin-phenothiazine-combination-as-potential-neuroblastoma-treatment-using-machine-learning 2025-12-29T19:40:47+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-neffy-as-first-community-use-epinephrine-product-for-severe-allergic-reactions 2025-12-29T19:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/azenta-divests-b-medical-systems-for-63-million-to-focus-on-core-life-sciences-portfolio 2025-12-29T19:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/setrusumab-phase-3-trials-in-osteogenesis-imperfecta-show-mixed-results-across-age-groups 2025-12-29T19:33:46+00:00 hourly 0.9 https://trial.medpath.com/news/unicycive-therapeutics-resubmits-nda-for-novel-phosphate-binder-targeting-hyperphosphatemia-in-dialysis-patients 2025-12-29T19:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-discontinues-acasunlimab-development-to-focus-on-late-stage-pipeline-programs 2025-12-29T19:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/theriva-biologics-receives-ema-scientific-advice-for-vcn-01-phase-3-trial-in-metastatic-pancreatic-cancer 2025-12-29T19:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/cel-sci-advances-multikine-toward-registration-with-212-patient-confirmatory-study-for-head-and-neck-cancer 2025-12-29T19:30:46+00:00 hourly 0.9 https://trial.medpath.com/news/zevra-therapeutics-expands-global-access-to-miplyffa-through-distribution-partnership-with-uniphar 2025-12-29T19:30:34+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-advances-tnx-4800-monoclonal-antibody-for-lyme-disease-prevention-with-fda-meeting-planned-for-2026 2025-12-29T19:30:20+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-secures-20-million-funding-to-advance-fibromyalgia-treatment-and-pipeline-development 2025-12-29T19:29:54+00:00 hourly 0.9 https://trial.medpath.com/news/gensight-biologics-secures-eur2-9-million-in-latest-fundraising-round-for-gene-therapy-development 2025-12-29T18:28:08+00:00 hourly 0.9 https://trial.medpath.com/news/aspen-pharmacare-divests-1-6-billion-apac-operations-to-focus-on-glp-1-drug-production 2025-12-29T18:27:01+00:00 hourly 0.9 https://trial.medpath.com/news/adlai-nortye-partners-with-ask-pharm-in-230-million-deal-for-pan-ras-inhibitor-an9025-in-greater-china 2025-12-29T18:26:18+00:00 hourly 0.9 https://trial.medpath.com/news/transcenta-therapeutics-partners-with-eirgenix-to-license-continuous-biomanufacturing-platform-for-affordable-biologics 2025-12-29T18:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/intas-pharmaceuticals-partners-with-integrimedical-to-launch-india-s-first-needle-free-ivf-injection-system 2025-12-29T15:26:05+00:00 hourly 0.9 https://trial.medpath.com/news/corteva-and-hexagon-bio-launch-multi-million-dollar-joint-venture-for-nature-inspired-agricultural-and-pharmaceutical-solutions 2025-12-29T14:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/smart-nanoparticles-enable-disease-responsive-gene-therapy-for-osteoarthritis 2025-12-29T13:24:45+00:00 hourly 0.9 https://trial.medpath.com/news/fosun-pharmaceutical-faces-market-skepticism-over-200-million-green-valley-acquisition-amid-regulatory-concerns 2025-12-29T05:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/who-prequalifies-first-covid-19-rapid-antigen-tests-for-long-term-global-use 2025-12-29T01:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/catnon-trial-final-results-confirm-adjuvant-temozolomide-benefit-in-idh-mutant-anaplastic-glioma 2025-12-29T01:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/next-generation-mrna-vaccines-demonstrate-protective-effects-against-multidrug-resistant-enterobacteriaceae 2025-12-28T01:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-oculis-privosegtor-for-optic-neuritis-treatment 2025-12-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-halts-mid-stage-eczema-drug-trial-after-failing-to-meet-efficacy-targets 2025-12-27T21:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-at-home-brain-stimulation-device-for-depression-treatment 2025-12-27T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/irlab-advances-first-in-class-apathy-treatment-irl757-into-phase-ib-trial-for-parkinson-s-disease 2025-12-27T13:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-enters-largest-ever-clinical-trial-for-abdominal-aortic-aneurysm-treatment 2025-12-27T05:28:39+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-s-major-depressive-disorder-drug-fails-phase-2-trial-primary-endpoint 2025-12-26T21:29:54+00:00 hourly 0.9 https://trial.medpath.com/news/novel-plga-nanoparticle-system-enhances-cisplatin-silibinin-combination-for-cervical-cancer-treatment 2025-12-26T21:29:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-wave-of-spine-and-orthopedic-robotics-systems-in-2025 2025-12-26T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/novel-her2-targeting-nanoagent-enables-precise-antibody-delivery-for-cancer-treatment 2025-12-26T17:29:33+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-discontinues-mid-stage-eczema-trial-after-jnj-5939-fails-to-meet-efficacy-goals 2025-12-26T17:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-terminates-phase-2b-duplex-ad-study-of-jnj-95475939-following-interim-efficacy-analysis 2025-12-26T17:28:53+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-secures-brazilian-patent-for-a3-adenosine-receptor-agonists-in-sexual-dysfunction-treatment 2025-12-26T13:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/biofabri-and-bharat-biotech-advance-technology-transfer-for-mtbvac-tuberculosis-vaccine-to-expand-global-access 2025-12-26T13:31:08+00:00 hourly 0.9 https://trial.medpath.com/news/strides-pharma-us-facility-receives-four-fda-observations-following-routine-inspection 2025-12-26T13:30:35+00:00 hourly 0.9 https://trial.medpath.com/news/abl-bio-secures-55-million-from-eli-lilly-for-grabody-bispecific-antibody-platform-development 2025-12-26T09:40:24+00:00 hourly 0.9 https://trial.medpath.com/news/sk-chemicals-partners-with-nextgen-bioscience-to-advance-ai-driven-drug-discovery-platform 2025-12-26T09:39:08+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-taro-unit-recalls-17664-units-of-ciclopirox-shampoo-in-us-due-to-manufacturing-quality-issues 2025-12-26T09:38:42+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-advances-hlx22-phase-3-trial-for-her2-positive-gastric-cancer-at-asco-gi-2026 2025-12-26T09:38:39+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-launches-phase-3-trial-testing-ziltivekimab-for-coronary-plaque-reduction-after-heart-attack 2025-12-26T09:29:49+00:00 hourly 0.9 https://trial.medpath.com/news/tyra-biosciences-gains-s-p-biotechnology-index-inclusion-as-fgfr3-focused-pipeline-advances 2025-12-26T09:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/major-study-questions-tramadol-s-efficacy-for-chronic-pain-reveals-cardiovascular-risks 2025-12-26T09:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-world-s-first-ctla-4-antibody-for-neoadjuvant-colon-cancer-treatment 2025-12-26T09:20:49+00:00 hourly 0.9 https://trial.medpath.com/news/modalis-publishes-breakthrough-crispr-gene-activation-study-for-rare-muscular-dystrophy-treatment 2025-12-26T09:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-reveals-adhd-stimulants-work-through-brain-s-reward-and-alertness-centers-not-attention-networks 2025-12-26T09:19:32+00:00 hourly 0.9 https://trial.medpath.com/news/edgewise-therapeutics-reports-positive-phase-2-data-for-cardiac-sarcomere-modulator-edg-7500-in-hypertrophic-cardiomyopathy 2025-12-26T09:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/lexaria-s-dehydratech-semaglutide-shows-48-reduction-in-side-effects-compared-to-rybelsus-in-phase-1b-trial 2025-12-25T05:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-advances-two-clinical-trials-icalcaprant-for-depression-and-abbv-444-for-dry-eye-disease 2025-12-25T05:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/caliway-submits-ind-for-phase-2-study-of-cbl-514-combined-with-zepbound-for-weight-management 2025-12-25T05:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-reports-strong-q1-2026-results-with-redemplo-launch-success-and-promising-obesity-pipeline-data 2025-12-25T03:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/liquidia-loses-bid-to-dismiss-united-therapeutics-patent-lawsuit-over-yutrepia-lung-drug 2025-12-25T01:30:44+00:00 hourly 0.9 https://trial.medpath.com/news/microport-medbot-receives-nmpa-approval-for-unipath-bronchoscopic-surgical-robot-becomes-first-company-to-commercialize-full-spectrum-of-robotic-surgery-systems 2025-12-25T01:29:55+00:00 hourly 0.9 https://trial.medpath.com/news/adama-and-basf-partner-to-commercialize-novel-fungicide-gilboa-for-european-cereal-disease-management 2025-12-25T01:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/euda-health-launches-comprehensive-stem-cell-platform-in-china-with-national-clinical-network 2025-12-24T21:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/omeros-receives-fda-approval-for-first-in-class-ta-tma-therapy-yartemlea 2025-12-24T21:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/immucell-pivots-strategy-after-fda-setback-expands-first-defense-r-sales-force-by-50 2025-12-24T21:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/modified-measles-virus-shows-promise-as-novel-mesothelioma-treatment-in-preclinical-studies 2025-12-24T21:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/traditional-chinese-medicine-zishen-yutai-pill-demonstrates-significant-improvement-in-live-birth-rates-for-women-of-advanced-maternal-age 2025-12-24T21:29:17+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-s-bhv-7000-fails-to-meet-primary-endpoint-in-phase-2-major-depression-trial 2025-12-24T21:27:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-yartemlea-as-first-therapy-for-life-threatening-transplant-complication-ta-tma 2025-12-24T17:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/kp-2-covid-19-vaccines-demonstrate-sustained-70-effectiveness-over-12-months-in-major-us-study 2025-12-24T17:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/hksh-medical-group-partners-with-chinese-academy-cancer-hospital-to-expand-proton-therapy-access-in-greater-bay-area 2025-12-24T17:30:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-ever-ta-tma-therapy-narsoplimab-shows-61-response-rate-in-high-risk-patients 2025-12-24T17:28:08+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-s-anti-st2-antibody-9mw1911-receives-fda-ind-clearance-for-copd-phase-iia-trial 2025-12-24T17:27:31+00:00 hourly 0.9 https://trial.medpath.com/news/singlera-genomics-partners-with-pure-medical-to-expand-dna-methylation-cancer-detection-technology-across-europe 2025-12-24T13:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/italfarmaco-and-jcr-pharmaceuticals-form-strategic-partnership-to-commercialize-givinostat-for-duchenne-muscular-dystrophy-in-japan 2025-12-24T13:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-bevacizumab-for-metastatic-colorectal-cancer-following-biosimilar-availability 2025-12-24T13:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/agenus-reports-promising-results-for-botensilimab-balstilimab-combination-in-treatment-refractory-ovarian-cancer 2025-12-24T05:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-extended-depth-of-focus-contact-lens-for-presbyopia-treatment 2025-12-24T05:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-drives-pharmaceutical-manufacturing-reshoring-initiative-as-industry-faces-supply-chain-vulnerabilities 2025-12-24T03:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/panitumumab-emerges-as-viable-alternative-to-cetuximab-in-braf-mutated-colorectal-cancer-treatment 2025-12-24T01:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/structure-therapeutics-oral-obesity-drug-gsbr-1290-advances-through-phase-2-trials-amid-valuation-concerns 2025-12-24T01:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-tevimbra-for-rare-throat-cancer-marking-first-immunotherapy-option-for-nasopharyngeal-carcinoma 2025-12-24T01:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/sn-bioscience-secures-fda-orphan-drug-designation-for-nanoparticle-cancer-drug-snb-101-in-gastric-cancer 2025-12-24T01:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/janux-therapeutics-appoints-william-go-as-chief-medical-officer-to-lead-clinical-development 2025-12-24T01:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-achieve-complete-alzheimer-s-reversal-in-mouse-models-through-nad-restoration 2025-12-24T01:30:40+00:00 hourly 0.9 https://trial.medpath.com/news/vaccinex-secures-60-million-to-advance-phase-2b-trial-of-alzheimer-s-drug-pepinemab 2025-12-23T21:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-shows-direct-cartilage-protective-effects-in-osteoarthritis-beyond-weight-loss 2025-12-23T21:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-edwards-sapien-m3-as-first-transseptal-mitral-valve-replacement-system 2025-12-23T21:29:04+00:00 hourly 0.9 https://trial.medpath.com/news/monoclonal-antibody-nebokitug-shows-promise-for-rare-liver-disease-primary-sclerosing-cholangitis 2025-12-23T21:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/lixte-biotechnology-doubles-enrollment-in-ovarian-clear-cell-cancer-trial-combining-lb-100-with-gsk-s-dostarlimab 2025-12-23T17:41:48+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-secures-5-million-funding-and-restructures-debt-to-advance-continuous-glucose-monitoring-technology 2025-12-23T17:41:07+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-secures-full-global-manufacturing-rights-for-adalimumab-biosimilar-hulio 2025-12-23T17:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/nature-cell-advances-vascostem-cli-development-with-nobel-laureate-advisory-support 2025-12-23T17:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/windtree-therapeutics-divests-cardiovascular-pipeline-to-seismic-pharmaceutical-holdings-in-strategic-asset-sale 2025-12-23T17:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-cobenfy-first-novel-schizophrenia-therapy-in-over-70-years 2025-12-23T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/asahi-kasei-pharma-expands-autoimmune-disease-pipeline-through-strategic-license-deal-and-r-d-hub-relocation 2025-12-23T17:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-recommends-second-phase-3-trial-for-reviva-s-brilaroxazine-in-schizophrenia-treatment 2025-12-23T17:29:45+00:00 hourly 0.9 https://trial.medpath.com/news/dinaqor-unveils-breakthrough-catheter-based-platform-for-precision-gene-therapy-delivery 2025-12-23T17:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/coya-therapeutics-receives-health-canada-approval-to-expand-als-trial-to-canadian-sites 2025-12-23T17:26:59+00:00 hourly 0.9 https://trial.medpath.com/news/brainsway-secures-major-insurance-coverage-expansions-for-deep-tms-therapy-in-adolescent-depression 2025-12-23T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/leads-biolabs-and-dianthus-therapeutics-initiate-phase-1-trial-of-novel-bifunctional-autoimmune-therapy-lbl-047 2025-12-23T13:35:12+00:00 hourly 0.9 https://trial.medpath.com/news/kashiv-biosciences-secures-77-million-financing-to-build-india-s-largest-single-use-biologics-manufacturing-facility 2025-12-23T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/initiator-pharma-begins-patient-enrollment-for-first-vulvodynia-treatment-study 2025-12-23T13:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/biomerica-s-infoods-ibs-test-shows-59-response-rate-in-real-world-study-secures-300-medicare-payment 2025-12-23T13:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-dupixent-for-pediatric-asthma-in-children-aged-6-11-years 2025-12-23T09:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-completes-japan-s-largest-bio-cdmo-facility-with-world-class-bioreactor-capacity 2025-12-23T05:30:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-final-guidance-on-bioresearch-monitoring-inspection-practices-to-enhance-clinical-trial-oversight 2025-12-23T05:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/hope-biosciences-stem-cell-therapy-shows-significant-motor-function-improvements-in-phase-ii-parkinson-s-disease-trial 2025-12-23T05:27:40+00:00 hourly 0.9 https://trial.medpath.com/news/medipost-secures-140-million-funding-and-japan-partnership-to-advance-stem-cell-therapy-for-knee-osteoarthritis 2025-12-23T03:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/ab-science-secures-us-patent-for-masitinib-in-sickle-cell-disease-treatment-through-2040 2025-12-23T01:36:30+00:00 hourly 0.9 https://trial.medpath.com/news/eurofins-lancaster-laboratories-announces-147-million-expansion-creating-250-jobs-in-pennsylvania 2025-12-23T01:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/shield-therapeutics-secures-fda-approval-extension-for-accrufer-in-pediatric-patients-eyes-china-market-entry-in-q1-2026 2025-12-23T01:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/community-advisors-dramatically-improve-asthma-clinical-trial-outcomes-through-protocol-modifications 2025-12-23T01:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-s-phase-3-valbenazine-trial-for-dyskinetic-cerebral-palsy-fails-to-meet-primary-endpoints 2025-12-23T01:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/puma-biotechnology-joins-nasdaq-biotechnology-index-following-commercial-success-and-clinical-progress 2025-12-23T01:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-ferric-maltol-approval-to-adolescents-for-iron-deficiency-treatment 2025-12-23T01:28:04+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-acquires-first-u-s-manufacturing-facility-for-280m-in-maryland 2025-12-22T21:35:12+00:00 hourly 0.9 https://trial.medpath.com/news/trabectedin-olaparib-combination-shows-promise-for-advanced-soft-tissue-sarcoma-subgroups 2025-12-22T21:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/qalsody-shows-unprecedented-functional-recovery-in-sod1-als-patients-over-3-5-years-jama-neurology-study-reports 2025-12-22T21:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-develops-precision-antibody-drug-conjugate-for-trbc2-positive-t-cell-cancers 2025-12-22T21:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/niagen-bioscience-acquires-core-nad-patent-portfolio-from-queen-s-university-belfast 2025-12-22T21:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/prolific-risk-score-becomes-first-ipf-biomarker-accepted-into-fda-qualification-program 2025-12-22T21:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-full-approval-for-pimobendan-to-delay-congestive-heart-failure-in-dogs 2025-12-22T21:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/tofersen-shows-long-term-efficacy-in-rare-genetic-als-stabilizing-disease-and-improving-function-in-quarter-of-patients 2025-12-22T21:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/oryzon-secures-japanese-patent-for-iadademstat-combination-therapy-in-cancer-treatment 2025-12-22T17:39:41+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapeutics-reports-promising-results-for-zugo-cel-car-t-therapy-in-autoimmune-diseases-and-blood-cancers 2025-12-22T17:36:42+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-x-labs-files-patent-for-quantum-enhanced-clinical-trial-technology 2025-12-22T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/immutep-s-first-in-class-lag-3-agonist-shows-promising-immunosuppressive-effects-in-phase-i-autoimmune-disease-trial 2025-12-22T17:36:08+00:00 hourly 0.9 https://trial.medpath.com/news/atea-pharmaceuticals-completes-enrollment-in-phase-3-hepatitis-c-trial-with-novel-drug-combination 2025-12-22T17:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/aqualung-therapeutics-receives-fda-clearance-for-phase-2a-progressive-pulmonary-fibrosis-trial 2025-12-22T17:34:56+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-celiac-investments-funds-rheumagen-s-hla-gene-editing-platform-for-celiac-disease-treatment 2025-12-22T17:34:31+00:00 hourly 0.9 https://trial.medpath.com/news/ema-identifies-38-cases-of-t-cell-malignancies-following-car-t-cell-therapy 2025-12-22T17:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/summit-therapeutics-submits-bla-for-ivonescimab-in-egfr-mutated-nsclc-as-analysts-spotlight-phase-iii-pipeline 2025-12-22T17:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/r-pharm-advances-three-cancer-drugs-through-clinical-development-including-novel-antiandrogen-for-prostate-cancer 2025-12-22T17:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/huonslab-submits-biologics-license-application-for-recombinant-human-hyaluronidase-hydizymetm 2025-12-22T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/arrivent-initiates-pivotal-phase-3-alpacca-trial-for-firmonertinib-in-egfr-pacc-mutant-nsclc 2025-12-22T17:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/pt-112-demonstrates-promising-efficacy-in-recurrent-thymoma-phase-2-trial 2025-12-22T17:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/transcode-therapeutics-appoints-jack-e-stover-to-board-of-directors-to-strengthen-rna-and-immuno-oncology-leadership 2025-12-22T17:31:20+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-nature-study-reveals-alzheimer-s-disease-prevalence-soars-to-65-in-adults-over-90 2025-12-22T17:30:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-dermatology-drug-labels-in-2025-with-five-new-indications-across-multiple-skin-conditions 2025-12-22T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/flagship-pioneering-and-repertoire-immune-medicines-partner-with-pfizer-to-develop-tcr-bispecifics-for-metastatic-prostate-cancer 2025-12-22T17:29:25+00:00 hourly 0.9 https://trial.medpath.com/news/uk-clinical-trials-activity-surges-9-as-ps50m-research-centre-and-regulatory-reforms-drive-innovation 2025-12-22T17:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-finalizes-guidance-on-clinical-trial-participation-mandating-broader-eligibility-and-real-world-population-representation 2025-12-22T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-corcept-s-relacorilant-in-hypercortisolism-treatment 2025-12-22T15:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/faron-launches-blaze-trial-with-icr-to-test-novel-approach-for-overcoming-immunotherapy-resistance 2025-12-22T13:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/korean-pharmaceutical-industry-faces-3-6-trillion-won-annual-loss-from-government-s-generic-drug-price-cut-plan 2025-12-22T13:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-japan-secures-first-esr1-mutation-liquid-biopsy-approval-for-breast-cancer-treatment-selection 2025-12-22T13:38:16+00:00 hourly 0.9 https://trial.medpath.com/news/iit-madras-and-australian-researchers-develop-precision-nanoinjection-platform-for-targeted-breast-cancer-treatment 2025-12-22T13:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-secures-japanese-approval-for-tecentriq-in-rare-thymic-carcinoma 2025-12-22T13:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-finerenone-gains-regulatory-momentum-for-heart-failure-treatment-across-global-markets 2025-12-22T13:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-zynyz-for-first-line-treatment-of-advanced-anal-cancer 2025-12-22T13:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-ceralasertib-imfinzi-combination-fails-phase-3-lung-cancer-trial-while-enhertu-gains-fda-breakthrough-designation 2025-12-22T13:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-acquires-radicava-business-from-tanabe-pharma-for-2-5-billion-to-strengthen-rare-disease-portfolio 2025-12-22T13:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/zambon-biotech-initiates-phase-3b-trial-for-novel-parkinson-s-disease-treatment-ipx203 2025-12-22T13:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-identifies-prostate-cancer-patients-unlikely-to-benefit-from-cabazitaxel-chemotherapy 2025-12-22T13:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/mondego-bio-advances-ai-designed-ptpn2-inhibitor-ze00-0388-to-phase-1-clinical-trials 2025-12-22T13:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-latify-phase-iii-trial-of-ceralasertib-plus-imfinzi-fails-to-meet-primary-endpoint-in-advanced-lung-cancer 2025-12-22T09:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/abl-bio-and-neok-bio-advance-first-in-class-bispecific-adc-abl206-to-phase-1-clinical-trial 2025-12-22T09:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-launches-one-on-one-pre-application-meetings-to-accelerate-drug-approvals-under-1-mechanism 2025-12-22T09:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-secures-global-rights-to-novel-lrrc15-targeting-adc-in-1-06-billion-deal-with-simcere-zaiming 2025-12-22T09:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-expands-oncology-partnership-with-universite-de-montreal-and-iricor-adding-two-map-kinase-related-discovery-programs 2025-12-22T09:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/telix-pharmaceuticals-advances-china-phase-3-trial-for-illuccix-while-addressing-fda-regulatory-challenges 2025-12-22T09:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/polyrizon-submits-fda-pre-request-for-pl-16-viral-blocker-with-over-90-efficacy-against-respiratory-viruses 2025-12-22T09:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/granules-pharmaceuticals-receives-tentative-fda-approval-for-generic-adhd-treatment 2025-12-22T09:28:39+00:00 hourly 0.9 https://trial.medpath.com/news/entera-bio-reports-breakthrough-in-oral-pth-therapy-for-hypoparathyroidism-with-once-daily-tablet 2025-12-22T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/pluri-expands-manufacturing-partnership-with-remedy-cell-achieves-clinical-grade-production-for-fibrotic-disease-therapy 2025-12-22T06:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/windward-bio-secures-700m-licensing-deal-for-dual-target-bispecific-antibody-win027 2025-12-22T05:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/us-fda-updates-safety-reporting-guidelines-for-bioavailability-and-bioequivalence-studies-indian-pharma-industry-responds-positively 2025-12-22T05:28:41+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-predicts-crohn-s-disease-years-before-symptoms-emerge-opening-door-to-prevention 2025-12-22T05:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-pharmaceuticals-ai-discovered-drug-rec-4881-shows-promise-in-phase-1b-2-fap-trial 2025-12-22T05:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/samyang-biopharmaceuticals-advances-mrna-therapy-for-idiopathic-pulmonary-fibrosis-using-sens-gene-delivery-platform 2025-12-22T05:28:27+00:00 hourly 0.9 https://trial.medpath.com/news/content-not-suitable-for-medical-publication 2025-12-22T05:28:03+00:00 hourly 0.9 https://trial.medpath.com/news/memphasys-secures-eur525000-european-supply-deal-for-felix-sperm-isolation-technology 2025-12-22T05:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-establishes-real-world-study-center-to-accelerate-drug-development-in-greater-bay-area 2025-12-22T05:27:54+00:00 hourly 0.9 https://trial.medpath.com/news/neuren-pharmaceuticals-advances-first-ever-phase-3-trial-for-phelan-mcdermid-syndrome-with-promising-phase-2-results 2025-12-22T05:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/telix-pharmaceuticals-achieves-positive-phase-3-results-for-prostate-cancer-imaging-agent-in-china 2025-12-22T01:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/scienture-secures-patent-protection-for-rezenopy-highest-strength-naloxone-nasal-spray-ahead-of-q2-2026-launch 2025-12-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/wasatch-biolabs-partners-with-agilent-to-advance-native-read-targeted-sequencing-technology 2025-12-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-launches-expanded-type-1-diabetes-screening-program-as-genetic-risk-tools-show-promise-for-early-detection 2025-12-21T21:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/rna-drug-pioneer-ribobio-passes-hong-kong-ipo-hearing-with-2b-partnership-portfolio 2025-12-21T21:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/zasocitinib-shows-phase-3-superiority-over-apremilast-in-dermatology-trials 2025-12-21T21:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-s-bhv-1510-shows-promising-early-cancer-data-in-combination-trial 2025-12-21T17:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/arcturus-therapeutics-faces-59-stock-decline-following-mixed-cystic-fibrosis-trial-results 2025-12-21T17:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/antisense-oligonucleotide-therapy-reverses-developmental-defects-in-spinal-muscular-atrophy-organoids 2025-12-21T17:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/t-maximum-s-allogeneic-car-t-therapy-mt027-receives-fda-clearance-for-phase-ii-glioblastoma-trial 2025-12-21T17:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/jacobio-pharma-partners-with-astrazeneca-in-2-billion-pan-kras-inhibitor-deal 2025-12-21T17:28:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-turkish-scientist-s-lung-cancer-drug-for-clinical-trials-after-six-years-of-research 2025-12-21T17:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/mit-develops-needle-free-glucose-monitor-using-light-based-technology-for-diabetes-management 2025-12-21T13:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-antivirals-nirmatrelvir-ritonavir-and-molnupiravir-show-promise-in-reducing-cardiovascular-risks 2025-12-21T13:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/fruquintinib-sintilimab-combination-achieves-32-7-response-rate-in-advanced-pmmr-endometrial-cancer 2025-12-21T13:29:08+00:00 hourly 0.9 https://trial.medpath.com/news/sarasota-memorial-hospital-launches-gene-therapy-trials-for-bladder-cancer-treatment 2025-12-21T13:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/askbio-receives-fda-clearance-to-begin-phase-1-2-gene-therapy-trial-for-late-onset-pompe-disease 2025-12-21T05:29:40+00:00 hourly 0.9 https://trial.medpath.com/news/moonlake-receives-fda-clearance-for-sonelokimab-bla-submission-in-hidradenitis-suppurativa-without-additional-trials 2025-12-21T05:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-novel-ethyl-cellulose-injection-system-for-cervical-dysplasia-treatment 2025-12-21T05:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/novel-sflt-1-and-paclitaxel-combination-therapy-shows-synergistic-anti-tumor-effects-in-3d-breast-cancer-models 2025-12-21T05:29:17+00:00 hourly 0.9 https://trial.medpath.com/news/exelixis-and-merck-launch-phase-3-litespark-033-trial-testing-novel-kidney-cancer-combination-therapy 2025-12-21T05:29:14+00:00 hourly 0.9 https://trial.medpath.com/news/zimbabwe-launches-groundbreaking-long-acting-hiv-prevention-injection-in-12-priority-districts 2025-12-21T05:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/kalaris-therapeutics-secures-50-million-funding-to-advance-th103-for-neovascular-amd-treatment 2025-12-20T21:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/multistage-malaria-vaccine-achieves-54-efficacy-in-phase-2-trial-among-malian-adults 2025-12-20T21:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/crinetics-pharmaceuticals-advances-phase-3-cah-trial-despite-leadership-transition 2025-12-20T21:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-viridian-therapeutics-veligrotug-for-thyroid-eye-disease 2025-12-20T21:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-and-regeneron-launch-real-world-studies-to-strengthen-dupilumab-s-evidence-base-across-multiple-inflammatory-conditions 2025-12-20T21:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-partners-with-myriad-genetics-to-bring-advanced-cancer-risk-assessment-tests-to-india 2025-12-20T21:28:47+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-strikes-historic-deal-with-u-s-government-to-provide-free-eliquis-to-medicaid-patients 2025-12-20T17:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/tucatinib-approved-for-pbs-listing-offering-4500-monthly-savings-for-metastatic-breast-cancer-patients 2025-12-20T17:27:47+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-files-ipo-registration-for-diabetes-business-minimed-targeting-nasdaq-listing 2025-12-20T13:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/cytokinetics-secures-fda-approval-for-myqorzo-breaking-bristol-myers-squibb-s-monopoly-in-hypertrophic-cardiomyopathy 2025-12-20T13:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-partners-with-ltz-therapeutics-to-develop-novel-myeloid-cell-engager-immunotherapies 2025-12-20T09:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/cms-proposes-international-reference-pricing-models-to-reduce-medicare-drug-costs 2025-12-20T05:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-official-s-skepticism-triggers-disc-medicine-stock-decline-amid-bitopertin-review 2025-12-20T05:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/sharp-therapeutics-secures-10m-funding-to-advance-gaucher-disease-treatment-toward-phase-i-trials 2025-12-20T05:28:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-ema-release-joint-guidelines-for-ai-in-drug-development-as-regulatory-agencies-advance-framework-for-healthcare-ai 2025-12-20T03:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/ai-and-precision-medicine-drive-clinical-trial-innovation-as-industry-prepares-for-2026-transformation 2025-12-20T03:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-qualifies-first-surrogate-endpoint-for-osteoporosis-drug-development-accelerating-clinical-trials 2025-12-20T02:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-secures-government-agreement-to-lower-drug-costs-and-expand-patient-access 2025-12-20T02:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-and-partners-advance-two-major-lung-cancer-trials-targeting-kras-g12c-and-trop2-positive-tumors 2025-12-20T00:26:11+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-secures-u-s-government-agreement-to-reduce-respiratory-drug-prices-by-up-to-66-for-40-million-americans 2025-12-20T00:23:40+00:00 hourly 0.9 https://trial.medpath.com/news/trump-executive-order-reclassifies-cannabis-to-schedule-iii-opening-new-clinical-research-opportunities 2025-12-19T21:38:05+00:00 hourly 0.9 https://trial.medpath.com/news/nimbus-therapeutics-completes-dose-escalation-for-novel-wrn-inhibitor-ndi-219216-in-msi-h-tumors 2025-12-19T21:37:54+00:00 hourly 0.9 https://trial.medpath.com/news/iba-acquires-belgian-radiochemistry-pioneer-ora-to-strengthen-nuclear-medicine-portfolio 2025-12-19T21:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/nxera-pharma-regains-rights-to-phase-2-ready-schizophrenia-drug-after-boehringer-ingelheim-declines-licensing-option 2025-12-19T21:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-direct-contracting-model-with-venture-capital-firms-to-accelerate-healthcare-innovation 2025-12-19T21:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/prophase-labs-and-advanced-biological-laboratories-announce-strategic-reverse-merger-to-create-global-diagnostics-platform 2025-12-19T21:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejection-of-low-dose-atropine-sparks-industry-petition-and-calls-for-myopia-reclassification 2025-12-19T21:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/merck-announces-historic-agreement-with-u-s-government-to-expand-drug-access-and-introduce-first-oral-pcsk9-inhibitor 2025-12-19T21:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-reaches-agreement-with-us-government-to-lower-drug-prices-and-expand-manufacturing 2025-12-19T21:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/chitose-laboratory-and-fujifilm-biosciences-form-strategic-alliance-to-advance-biopharmaceutical-manufacturing 2025-12-19T21:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-and-biontech-launch-phase-1-2-trial-testing-pumitamig-in-first-line-hepatocellular-carcinoma 2025-12-19T21:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/altamira-therapeutics-secures-china-approval-for-bentrio-nasal-spray-in-allergic-rhinitis-market 2025-12-19T21:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/presidential-executive-order-reclassifies-cannabis-accelerating-defloria-s-phase-2-autism-drug-development 2025-12-19T21:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/repurposed-cancer-drug-sargramostim-shows-promise-in-halting-brain-cell-death-in-alzheimer-s-disease 2025-12-19T21:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/claros-technologies-achieves-99-99-pfas-destruction-at-commercial-scale-with-clarostechuv-platform 2025-12-19T21:30:04+00:00 hourly 0.9 https://trial.medpath.com/news/galectin-therapeutics-receives-fda-feedback-on-belapectin-mash-cirrhosis-program-secures-10-million-financing 2025-12-19T17:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-secures-major-drug-pricing-deals-with-pharmaceutical-giants-mandates-us-manufacturing-expansion 2025-12-19T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/catheter-precision-expands-locket-device-to-ireland-s-largest-electrophysiology-center 2025-12-19T17:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/psyence-biomed-secures-regulatory-approval-for-nature-derived-psilocybin-in-phase-iib-cancer-adjustment-disorder-trial 2025-12-19T17:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-acquires-amicus-therapeutics-for-4-8-billion-to-expand-rare-disease-portfolio 2025-12-19T17:30:50+00:00 hourly 0.9 https://trial.medpath.com/news/niowave-expands-10-year-actinium-225-supply-agreement-with-astrazeneca-for-advanced-cancer-therapies 2025-12-19T17:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-confirms-280m-radioligand-therapy-manufacturing-facility-in-denton-texas 2025-12-19T17:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/bimekizumab-shows-sustained-three-year-efficacy-in-hidradenitis-suppurativa-as-treatment-landscape-expands 2025-12-19T17:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-determines-andexxa-risks-outweigh-benefits-astrazeneca-to-withdraw-anticoagulant-reversal-agent 2025-12-19T17:30:06+00:00 hourly 0.9 https://trial.medpath.com/news/uk-government-launches-major-initiative-to-improve-brain-tumour-clinical-trial-access-through-nhs-app-integration 2025-12-19T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/resveratrol-copper-combination-shows-promise-against-glioblastoma-in-early-clinical-trial 2025-12-19T17:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-grifols-fesilty-for-congenital-fibrinogen-deficiency-treatment 2025-12-19T17:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/vtv-therapeutics-initiates-phase-2-trial-of-cadisegliatin-for-type-2-diabetes-in-middle-east-and-north-africa 2025-12-19T13:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-and-teva-secure-u-s-settlement-for-eylea-biosimilar-avt06-launch-in-q4-2026 2025-12-19T13:30:38+00:00 hourly 0.9 https://trial.medpath.com/news/ema-committee-recommends-vueway-for-pediatric-patients-under-2-years-addressing-critical-unmet-need-in-neonatal-imaging 2025-12-19T13:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-st-andrews-develops-revolutionary-method-to-convert-plastic-waste-into-cancer-drug-building-blocks 2025-12-19T13:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/athira-pharma-acquires-late-stage-breast-cancer-drug-lasofoxifene-in-90-million-deal 2025-12-19T09:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/syneron-bio-secures-nearly-100m-series-a-funding-for-macrocyclic-peptide-platform 2025-12-19T09:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/rezubio-secures-20-million-series-a-to-advance-novel-membrane-anchored-drug-platform-for-obesity-and-diabetes 2025-12-19T09:30:26+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-s-phase-ii-falkon-trial-for-ultra-rare-bone-disease-fop-fails-to-meet-primary-endpoint 2025-12-19T09:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-subcutaneous-pembrolizumab-formulation-developed-through-space-station-research 2025-12-19T09:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-s-nu-9-drug-prevents-alzheimer-s-pathology-in-pre-symptomatic-animal-model 2025-12-19T09:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/home-based-gamma-brain-stimulation-shows-promise-for-early-alzheimer-s-disease-in-randomized-trial 2025-12-19T05:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/trump-executive-order-accelerates-medical-cannabis-research-as-mmj-international-holdings-prepares-fda-ready-pharmaceutical-formulations 2025-12-19T05:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/telo-genomics-launches-blood-based-mrd-study-for-multiple-myeloma-with-university-of-athens 2025-12-19T05:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/meiji-seika-pharma-partners-with-mbc-biolabs-to-accelerate-drug-discovery-innovation 2025-12-19T05:28:43+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-research-embraces-patient-centric-innovation-through-agile-cro-partnerships-and-digital-transformation 2025-12-19T01:51:59+00:00 hourly 0.9 https://trial.medpath.com/news/annovis-bio-launches-36-month-open-label-extension-study-for-buntanetap-in-parkinson-s-disease 2025-12-19T01:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/neuraworx-secures-oversubscribed-seed-funding-to-advance-first-in-class-cerebrovascular-pacing-system-for-cns-disorders 2025-12-19T01:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-partners-with-camp4-therapeutics-in-440m-rna-deal-for-neurodegenerative-and-kidney-diseases 2025-12-19T01:32:44+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-tyk2-inhibitor-glpg3667-meets-primary-endpoint-in-dermatomyositis-phase-3-enabling-study 2025-12-19T01:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/cartesian-therapeutics-appoints-car-t-pioneer-adrian-bot-to-board-of-directors 2025-12-19T01:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/larimar-therapeutics-advances-toward-q2-2026-bla-submission-for-friedreich-s-ataxia-treatment 2025-12-19T01:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-radiation-therapy-shows-promise-for-high-risk-renal-cell-carcinoma-with-vascular-invasion 2025-12-19T01:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-awards-1-6-million-grant-for-controversial-hepatitis-b-vaccine-study-in-guinea-bissau 2025-12-19T01:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-s-amplatzer-piccolo-delivery-system-receives-fda-clearance-for-treating-heart-defects-in-premature-infants 2025-12-19T01:28:33+00:00 hourly 0.9 https://trial.medpath.com/news/werewolf-therapeutics-reports-promising-clinical-data-for-cancer-immunotherapies-advances-t-cell-engager-pipeline 2025-12-18T21:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/oncozenge-submits-phase-iii-clinical-trial-application-for-bupizenge-in-cancer-related-oral-pain 2025-12-18T21:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/minaris-and-cell-and-gene-therapy-catapult-form-strategic-partnership-to-advance-viral-vector-manufacturing 2025-12-18T21:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-ceo-s-9-36-million-performance-award-tied-to-gene-therapy-regulatory-milestones 2025-12-18T21:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/almirall-advances-lad603-from-phase-1-completion-to-phase-2-trial-for-severe-alopecia-areata 2025-12-18T21:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-gsk-s-exdensur-as-first-ultra-long-acting-biologic-for-severe-asthma 2025-12-18T21:29:30+00:00 hourly 0.9 https://trial.medpath.com/news/cocrystal-pharma-advances-first-oral-norovirus-antiviral-cdi-988-into-phase-1b-human-challenge-study 2025-12-18T17:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/cybin-transitions-to-nasdaq-with-new-help-ticker-as-helus-pharma-advancing-phase-3-depression-treatment 2025-12-18T17:47:35+00:00 hourly 0.9 https://trial.medpath.com/news/exelixis-and-natera-launch-phase-3-trial-testing-zanzalintinib-in-mrd-positive-colorectal-cancer-patients 2025-12-18T17:44:20+00:00 hourly 0.9 https://trial.medpath.com/news/actinogen-completes-enrollment-in-pivotal-alzheimer-s-trial-with-247-participants 2025-12-18T17:40:53+00:00 hourly 0.9 https://trial.medpath.com/news/aztreonam-avibactam-shows-noninferior-efficacy-against-carbapenem-resistant-infections-in-open-label-trial 2025-12-18T17:40:24+00:00 hourly 0.9 https://trial.medpath.com/news/novel-zwitterionic-lipids-reduce-mrna-vaccine-inflammation-while-boosting-antigen-expression 2025-12-18T17:38:49+00:00 hourly 0.9 https://trial.medpath.com/news/very-low-dose-oral-immunotherapy-shows-promise-for-children-with-multiple-food-allergies 2025-12-18T17:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/bd-partners-with-penn-institute-to-advance-immunotherapy-research-through-high-parameter-flow-cytometry 2025-12-18T17:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-secures-54-3-million-cepi-funding-for-first-mrna-bird-flu-vaccine-pivotal-trial 2025-12-18T17:37:48+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-trial-of-azathioprine-fails-to-meet-primary-endpoint-in-early-parkinson-s-disease 2025-12-18T17:37:45+00:00 hourly 0.9 https://trial.medpath.com/news/salarius-pharmaceuticals-rebrands-as-decoy-therapeutics-pivots-to-ai-driven-antiviral-platform 2025-12-18T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/news/liom-achieves-breakthrough-in-non-invasive-glucose-monitoring-technology-extends-series-a-to-chf-38-million 2025-12-18T17:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/pulmatrix-and-cullgen-mutually-waive-no-solicitation-clause-while-awaiting-chinese-regulatory-approval-for-merger 2025-12-18T17:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-receives-7-5-million-grant-to-lead-international-autism-clinical-trials-network 2025-12-18T17:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/pyxis-oncology-reports-promising-phase-1-results-for-novel-adc-micvo-in-head-and-neck-cancer 2025-12-18T17:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-india-receives-cdsco-approval-for-datopotamab-deruxtecan-in-hr-positive-her2-negative-breast-cancer 2025-12-18T17:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-s-zasocitinib-achieves-phase-3-success-in-moderate-to-severe-plaque-psoriasis 2025-12-18T17:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/avadel-completes-enrollment-in-phase-3-trial-of-lumryz-for-idiopathic-hypersomnia 2025-12-18T17:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/athira-pharma-secures-236-million-financing-and-exclusive-rights-to-lasofoxifene-for-esr1-mutant-metastatic-breast-cancer 2025-12-18T17:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-achieves-four-major-regulatory-milestones-across-diverse-pipeline-including-gene-therapy-and-generic-approvals 2025-12-18T17:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/memo-therapeutics-potravitug-receives-eu-orphan-designation-for-bk-polyomavirus-infection-in-kidney-transplant-patients 2025-12-18T17:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/century-health-and-tessel-biosciences-partner-to-leverage-ai-curated-real-world-data-for-copd-drug-development 2025-12-18T17:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/havih-envirosciences-partners-with-andhra-pradesh-government-to-establish-bsl-4-anti-infective-drug-development-facility 2025-12-18T17:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/lixte-biotechnology-raises-4-3-million-to-advance-cancer-treatment-development 2025-12-18T17:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/tislelizumab-plus-chemoradiotherapy-shows-superior-response-rates-in-gastric-cancer-trial 2025-12-18T17:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/beone-medicines-receives-fda-fast-track-designation-for-novel-bispecific-antibody-in-hepatocellular-carcinoma 2025-12-18T17:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ind-and-grants-fast-track-designation-for-cbi-1214-t-cell-engager-in-colorectal-cancer 2025-12-18T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-expanded-indication-for-johnson-johnson-s-trufill-n-bca-system-in-chronic-subdural-hematoma-treatment 2025-12-18T17:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/syremis-therapeutics-launches-with-165m-series-a-to-advance-novel-mental-health-therapies 2025-12-18T17:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/usc-launches-phase-2b-trial-of-stem-cell-retinal-implant-for-advanced-dry-age-related-macular-degeneration 2025-12-18T13:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/forx-therapeutics-secures-50m-series-a-to-advance-parg-inhibitor-for-parp-resistant-cancers 2025-12-18T09:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/sequana-medical-secures-key-u-s-patent-for-dsr-heart-failure-therapy 2025-12-18T09:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/cormedix-reports-72-reduction-in-bloodstream-infections-with-defencath-in-real-world-study 2025-12-18T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/circle-pharma-nominates-cid-165-as-second-oncology-program-targeting-cyclin-d1-driven-cancers 2025-12-18T05:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-presents-breakthrough-anti-fibrotic-data-for-obefazimod-at-ecco-2026-alongside-comprehensive-ulcerative-colitis-results 2025-12-18T05:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/prism-biolab-and-talus-bioscience-partner-to-target-previously-undruggable-protein-interactions-using-ai-guided-drug-discovery 2025-12-18T05:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/processa-pharmaceuticals-reports-promising-phase-2-data-for-ngc-cap-in-advanced-breast-cancer 2025-12-18T05:29:39+00:00 hourly 0.9 https://trial.medpath.com/news/alphamab-oncology-receives-ind-approval-for-first-in-class-pd-l1-vegfr2-bispecific-adc-jskn027 2025-12-18T05:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-shows-consistent-cardiovascular-benefits-regardless-of-heart-failure-status-in-surpass-cvot-trial 2025-12-18T05:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/heart-failure-pipeline-shows-strong-activity-with-70-companies-developing-75-therapeutic-candidates 2025-12-18T05:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/trump-signs-executive-order-reclassifying-cannabis-to-schedule-iii-opening-new-pathways-for-medical-research 2025-12-18T05:27:44+00:00 hourly 0.9 https://trial.medpath.com/news/cancervax-advances-universal-cancer-platform-with-successful-nanoparticle-and-smart-mrna-validation 2025-12-18T01:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/personalis-next-personal-test-demonstrates-ultrasensitive-ctdna-monitoring-capabilities-across-multiple-cancer-types 2025-12-18T01:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/hutchmed-s-hmpl-a251-becomes-first-antibody-targeted-therapy-conjugate-to-enter-clinical-development 2025-12-18T01:27:46+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-chicago-and-abbvie-extend-cancer-research-partnership-through-2027 2025-12-18T01:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-discontinues-brensocatib-development-in-chronic-rhinosinusitis-after-phase-2b-trial-failure 2025-12-18T01:27:35+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-air-expands-lungfit-ph-global-reach-to-39-countries-appoints-new-cfo 2025-12-17T21:37:37+00:00 hourly 0.9 https://trial.medpath.com/news/ustekinumab-demonstrates-superior-drug-survival-among-biologic-naive-psoriasis-patients-in-large-danish-registry-study 2025-12-17T21:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-pharmaceuticals-announces-250m-manufacturing-expansion-to-scale-rna-interference-therapeutics-production 2025-12-17T21:35:25+00:00 hourly 0.9 https://trial.medpath.com/news/nuvectis-pharma-initiates-phase-1b-combination-study-of-nxp900-with-osimertinib-for-resistant-egfr-mutated-nsclc 2025-12-17T21:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/veru-receives-fda-clarity-on-enobosarm-glp-1-combination-for-obesity-treatment-plans-phase-2b-plateau-study 2025-12-17T21:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-therapy-rejuvenates-aging-immune-systems-in-mice-boosting-vaccine-and-cancer-treatment-response 2025-12-17T21:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/biovaxys-reports-positive-phase-1-results-for-cancer-immunotherapies-in-breast-and-bladder-cancer 2025-12-17T21:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/dna-nanobots-raises-3-5m-to-advance-non-viral-gene-therapy-platform-using-dna-origami-technology 2025-12-17T21:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/insightec-spins-out-lotus-neuro-to-advance-focused-ultrasound-brain-therapies 2025-12-17T21:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ferumoxytol-as-novel-brain-cancer-imaging-agent-after-30-years-of-ohsu-research 2025-12-17T21:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/huxley-medical-receives-fda-clearance-for-ai-powered-central-sleep-apnea-detection-in-home-testing-device 2025-12-17T21:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-places-clinical-hold-on-merck-daiichi-sankyo-adc-after-fatal-lung-toxicity-events 2025-12-17T21:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/processa-pharmaceuticals-reports-promising-phase-2-data-for-ngc-cap-combination-in-metastatic-breast-cancer 2025-12-17T17:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/enveda-receives-fda-clearance-for-first-in-class-oral-obesity-therapy-env-308-doses-first-patient-in-phase-1-trial 2025-12-17T17:43:22+00:00 hourly 0.9 https://trial.medpath.com/news/traws-pharma-s-ratutrelvir-shows-promise-as-ritonavir-free-covid-19-treatment-in-phase-2-trial 2025-12-17T17:42:18+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-hawaii-researchers-identify-strategy-to-overcome-antibody-drug-conjugate-resistance-in-breast-cancer 2025-12-17T17:39:54+00:00 hourly 0.9 https://trial.medpath.com/news/short-course-tb-prevention-shows-promise-in-high-risk-populations-as-global-trials-advance 2025-12-17T17:39:32+00:00 hourly 0.9 https://trial.medpath.com/news/soligenix-reports-positive-phase-2a-results-for-sgx302-gel-formulation-in-mild-to-moderate-psoriasis 2025-12-17T17:37:30+00:00 hourly 0.9 https://trial.medpath.com/news/moleculin-s-wp1066-shows-promise-in-first-pediatric-brain-tumor-trial-warrants-phase-2-study 2025-12-17T17:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accelerated-cancer-drug-approvals-deliver-limited-survival-benefits-despite-20-billion-medicare-investment 2025-12-17T17:36:16+00:00 hourly 0.9 https://trial.medpath.com/news/half-dose-chemotherapy-proves-equally-effective-for-elderly-lymphoma-patients-in-real-world-study 2025-12-17T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/decode-age-secures-1-7-million-pre-series-a-funding-to-advance-longevity-science-and-gut-microbiome-research 2025-12-17T17:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-tnkase-for-acute-ischemic-stroke-first-new-stroke-treatment-in-nearly-27-years 2025-12-17T17:35:22+00:00 hourly 0.9 https://trial.medpath.com/news/4dmt-reports-positive-phase-1-data-for-gene-therapy-4d-710-in-cystic-fibrosis 2025-12-17T17:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/protalix-and-secarna-partner-to-develop-ai-powered-antisense-therapies-for-rare-kidney-diseases 2025-12-17T17:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/northstrive-biosciences-advances-ai-driven-drug-discovery-to-phase-iii-for-muscle-preservation-in-obesity-treatment 2025-12-17T17:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/pathmaker-neurosystems-receives-fda-breakthrough-device-designation-for-myoregulator-r-als-treatment 2025-12-17T17:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/peptinovo-biopharma-achieves-manufacturing-breakthrough-for-vitamin-e-based-cancer-prodrug-platform 2025-12-17T17:30:31+00:00 hourly 0.9 https://trial.medpath.com/news/updated-survival-data-from-flaura2-and-mariposa-trials-reshape-treatment-selection-in-egfr-mutated-advanced-nsclc 2025-12-17T17:28:33+00:00 hourly 0.9 https://trial.medpath.com/news/cuhk-launches-world-s-first-ai-powered-gut-microbiome-test-for-early-autism-detection 2025-12-17T17:28:04+00:00 hourly 0.9 https://trial.medpath.com/news/sol-gel-discontinues-sgt-210-development-for-darier-disease-after-phase-1b-trial-fails-to-show-efficacy 2025-12-17T13:35:48+00:00 hourly 0.9 https://trial.medpath.com/news/mrm-health-partners-with-netherlands-cancer-institute-to-develop-microbiome-therapies-for-cancer-immunotherapy 2025-12-17T13:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-tree-frog-gut-bacterium-achieves-complete-tumor-elimination-in-mice-with-single-dose 2025-12-17T13:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/asg-s-beta1-becomes-first-inhaled-erectile-dysfunction-therapy-to-receive-fda-ind-approval 2025-12-17T13:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/crbn-gene-mutations-show-variable-impact-on-myeloma-drug-response-enabling-precision-treatment-selection 2025-12-17T13:28:34+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-m-a-activity-surges-as-companies-brace-for-2026-patent-cliff 2025-12-17T09:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-s-biosimilar-ranibizumab-ranluspec-receives-positive-ema-committee-opinion-for-multiple-eye-conditions 2025-12-17T09:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-efdoralprin-alfa-receives-eu-orphan-designation-for-rare-lung-disease-treatment 2025-12-17T09:28:07+00:00 hourly 0.9 https://trial.medpath.com/news/kane-biotech-receives-health-canada-approval-for-revyve-antimicrobial-wound-gel-spray-presents-clinical-data-at-wound-healing-conference 2025-12-17T07:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/cosette-pharmaceuticals-launches-first-generic-cipro-hc-with-180-day-market-exclusivity 2025-12-17T05:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-partners-with-bristol-myers-squibb-in-1-1-billion-multi-specific-antibody-deal 2025-12-17T05:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-s-phase-3-trial-for-anti-gbm-disease-fails-primary-endpoint-despite-improved-dialysis-free-outcomes 2025-12-17T05:27:25+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-2026-outlook-falls-short-of-expectations-amid-patent-cliff-and-post-pandemic-transition 2025-12-17T03:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/beacon-therapeutics-initiates-landscape-trial-for-x-linked-retinitis-pigmentosa-gene-therapy 2025-12-17T01:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/cms-reconsiders-medicare-coverage-for-tavr-in-asymptomatic-aortic-stenosis-patients-following-edwards-request 2025-12-17T01:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/aktis-oncology-pursues-200-million-ipo-to-advance-early-stage-cancer-therapies 2025-12-17T01:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/cms-narrows-medicare-coverage-for-skin-substitutes-to-18-products-impacting-wound-care-market 2025-12-17T01:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/pelareorep-shows-33-response-rate-in-kras-mutant-colorectal-cancer-tripling-standard-of-care-outcomes 2025-12-17T01:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/aav-gene-therapy-shows-promise-for-inherited-retinal-disease-and-cardiac-dysfunction-in-preclinical-studies 2025-12-17T01:30:05+00:00 hourly 0.9 https://trial.medpath.com/news/inhibrx-biosciences-advances-two-oncology-programs-with-key-enrollment-milestones-and-upcoming-data-readouts 2025-12-17T01:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/dompe-initiates-phase-3-trial-of-dual-mechanism-isocyclosporin-for-atopic-keratoconjunctivitis 2025-12-17T01:28:05+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-secures-eur550-million-licensing-deal-with-norgine-for-hepatitis-delta-combination-therapy 2025-12-17T01:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/exozymes-achieves-100-fold-scale-up-of-nct-production-with-99-conversion-efficiency-using-cell-free-enzyme-platform 2025-12-17T01:27:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-brain-tumor-warning-for-depo-provera-after-pfizer-lawsuit-pressure 2025-12-17T01:27:27+00:00 hourly 0.9 https://trial.medpath.com/news/vyriad-s-vv169-in-vivo-car-t-therapy-achieves-100-tumor-clearance-in-multiple-myeloma-preclinical-studies 2025-12-16T21:36:54+00:00 hourly 0.9 https://trial.medpath.com/news/regenerative-medicine-advances-promise-functional-diabetes-cures-as-multiple-companies-report-clinical-progress 2025-12-16T21:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/trethera-secures-2-7-million-nih-grant-to-evaluate-tre-515-combination-therapy-for-kras-inhibitor-resistant-lung-cancer 2025-12-16T21:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/caris-life-sciences-partners-with-genentech-in-1-1-billion-oncology-target-discovery-collaboration 2025-12-16T21:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-stocks-rally-after-hours-on-fda-designations-and-clinical-trial-progress 2025-12-16T21:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-raises-100-million-through-convertible-bond-offering-to-fund-biosimilar-pipeline-expansion 2025-12-16T21:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/nephrology-advances-in-2025-fda-approvals-and-clinical-breakthroughs-transform-kidney-disease-treatment 2025-12-16T21:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-once-monthly-mirikizumab-regimen-for-ulcerative-colitis-as-real-world-data-shows-early-treatment-benefits 2025-12-16T21:28:59+00:00 hourly 0.9 https://trial.medpath.com/news/profocal-cooled-laser-therapy-demonstrates-84-local-control-rate-in-prostate-cancer-phase-2-trial 2025-12-16T21:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/nektar-therapeutics-advances-rezpegaldesleukin-despite-mixed-phase-2b-results-in-alopecia-areata 2025-12-16T21:28:05+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-biosciences-secures-multi-year-supply-agreement-for-alpha-emitting-radioisotopes-to-advance-targeted-cancer-therapies 2025-12-16T17:42:57+00:00 hourly 0.9 https://trial.medpath.com/news/immuneering-receives-fda-and-ema-alignment-for-phase-3-atebimetinib-trial-in-first-line-pancreatic-cancer 2025-12-16T17:41:20+00:00 hourly 0.9 https://trial.medpath.com/news/aeovian-pharmaceuticals-secures-55-million-series-b-to-advance-first-in-class-mtorc1-inhibitor-for-rare-epilepsy 2025-12-16T17:41:17+00:00 hourly 0.9 https://trial.medpath.com/news/verastem-oncology-restructures-leadership-to-advance-kras-targeted-cancer-pipeline 2025-12-16T17:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-secures-global-rights-to-third-generation-egfr-tki-aumolertinib-for-lung-cancer-treatment 2025-12-16T17:38:40+00:00 hourly 0.9 https://trial.medpath.com/news/beacon-biosignals-partners-with-harmony-biosciences-to-integrate-ai-driven-eeg-technology-in-phase-3-hypersomnia-trials 2025-12-16T17:36:26+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-toronto-and-moderna-partner-on-next-generation-mucosal-vaccines-and-ai-driven-mrna-therapeutics 2025-12-16T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/uk-partners-with-nobel-prize-winner-s-biotech-to-produce-cancer-therapies-from-nuclear-waste 2025-12-16T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/genflow-completes-dosing-phase-of-sirt6-gene-therapy-trial-in-dogs-with-no-adverse-events 2025-12-16T17:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/ratio-therapeutics-doses-first-patients-in-phase-1-2-trial-of-fap-targeted-radiopharmaceutical-for-aggressive-sarcomas 2025-12-16T17:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/affibody-s-aby-271-radioligand-therapy-advances-to-phase-i-part-b-following-positive-safety-data-in-her2-positive-breast-cancer 2025-12-16T17:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/evolveimmune-therapeutics-initiates-first-in-human-trial-of-evolve104-trispecific-t-cell-engager 2025-12-16T17:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/recludix-pharma-receives-fda-clearance-for-first-in-class-oral-stat6-inhibitor-rex-8756-to-enter-phase-1-testing 2025-12-16T17:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/xoma-royalty-acquires-gene-therapy-developer-generation-bio-for-4-29-per-share 2025-12-16T17:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/ember-lifesciences-raises-16-5m-series-a-to-address-35b-cold-chain-crisis-in-pharmaceutical-distribution 2025-12-16T17:34:03+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-elfabrio-for-fabry-disease-treatment-expanding-access-to-pegylated-enzyme-replacement-therapy 2025-12-16T17:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/humacyte-secures-77-5-million-credit-facility-to-support-bioengineered-tissue-platform-expansion 2025-12-16T17:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/checkmate-7dx-trial-shows-no-survival-benefit-for-nivolumab-plus-docetaxel-in-metastatic-prostate-cancer 2025-12-16T17:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-biopharma-advances-dual-phase-iii-programs-with-namodenoson-and-piclidenoson 2025-12-16T17:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/arch-biopartners-expands-phase-ii-trial-for-lsalt-peptide-with-st-michael-s-hospital-ethics-approval 2025-12-16T17:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/ambros-therapeutics-launches-with-125m-to-advance-non-opioid-pain-drug-neridronate-for-rare-disease-crps-1 2025-12-16T17:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/adagene-s-muzastotug-receives-fda-fast-track-designation-for-mss-colorectal-cancer 2025-12-16T17:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-licenses-tnx-4900-novel-sigma-1-receptor-antagonist-for-chronic-neuropathic-pain 2025-12-16T17:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-joins-baselaunch-as-sixth-pharmaceutical-partner-in-basel-biotech-incubator 2025-12-16T17:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/baseline-blood-parameters-predict-bcma-car-t-therapy-outcomes-in-multiple-myeloma-patients 2025-12-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/multi-target-nanoparticle-therapy-achieves-90-neuron-survival-in-alzheimer-s-models 2025-12-16T15:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/metis-techbio-advances-mrna-cancer-therapeutics-with-dual-publications-in-nature-communications-and-jitc 2025-12-16T13:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/atom-therapeutics-launches-phase-2-trial-of-abp-745-for-atherosclerotic-cardiovascular-disease 2025-12-16T13:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/allogene-secures-full-control-of-car-t-therapy-following-favorable-arbitration-ruling 2025-12-16T13:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/nicox-completes-key-data-generation-for-ncx-470-glaucoma-drug-nda-submission-planned-for-h1-2026 2025-12-16T13:30:05+00:00 hourly 0.9 https://trial.medpath.com/news/ab-science-s-ab8939-shows-promise-against-refractory-acute-myeloid-leukemia-with-novel-dual-target-mechanism 2025-12-16T09:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/manifold-bio-strengthens-leadership-team-with-coo-appointment-to-scale-ai-driven-drug-discovery-platform 2025-12-16T09:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/allergy-therapeutics-secures-first-german-approval-for-grassmuno-grass-pollen-immunotherapy 2025-12-16T09:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/psychedelic-therapies-advance-through-clinical-trials-as-hmnc-s-novel-ketamine-formulation-shows-promise 2025-12-16T09:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/biostar-pharma-initiates-pivotal-u-s-trial-for-utidelone-in-her2-negative-breast-cancer-brain-metastases 2025-12-16T09:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-companies-push-fda-to-modernize-manufacturing-regulations-to-support-us-drug-production 2025-12-16T09:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/allink-biotherapeutics-raises-47m-to-advance-two-adc-programs-in-global-phase-i-trials 2025-12-16T05:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-extends-review-timeline-for-aldeyra-s-reproxalap-dry-eye-treatment-to-march-2026 2025-12-16T05:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-voluntarily-withdraws-andexxa-from-us-market-following-fatal-thromboembolic-events 2025-12-16T05:26:44+00:00 hourly 0.9 https://trial.medpath.com/news/apac-region-emerges-as-global-clinical-trial-powerhouse-with-50000-expected-studies 2025-12-16T03:27:24+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-secures-1-04-billion-license-for-adel-y01-novel-tau-targeting-alzheimer-s-therapy 2025-12-16T01:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaessentia-reports-strong-besremi-growth-and-advances-pipeline-for-rare-blood-cancer-treatment 2025-12-16T01:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/attivare-therapeutics-secures-6-6-million-gates-foundation-grant-for-next-generation-malaria-vaccine 2025-12-16T01:34:20+00:00 hourly 0.9 https://trial.medpath.com/news/gensci-partners-with-rtw-investments-in-1-365-billion-deal-for-first-in-class-thyroid-autoimmune-disease-therapy 2025-12-16T01:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-eliminates-patient-data-requirements-for-real-world-evidence-in-medical-device-applications 2025-12-16T01:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/tempramed-secures-south-korean-patent-for-vivi-box-temperature-controlled-medication-storage-system 2025-12-16T01:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/mount-sinai-researchers-develop-cell-selective-mrna-therapy-platform-for-precision-cancer-treatment 2025-12-16T01:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/novel-apd-1-conjugated-nanodrugs-show-promise-for-overcoming-pancreatic-cancer-immunotherapy-barriers 2025-12-16T01:30:43+00:00 hourly 0.9 https://trial.medpath.com/news/nektar-therapeutics-to-report-phase-2b-results-for-alopecia-areata-treatment-rezpegaldesleukin 2025-12-16T01:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/io-biotech-s-cancer-vaccine-shows-25-5-month-median-progression-free-survival-in-five-year-melanoma-study 2025-12-16T01:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/organogenesis-initiates-rolling-bla-submission-for-renu-knee-osteoarthritis-treatment-following-fda-approval 2025-12-16T01:28:34+00:00 hourly 0.9 https://trial.medpath.com/news/mochida-and-duchesnay-partner-to-bring-first-pregnancy-nausea-treatment-to-japan 2025-12-16T01:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-eliminates-real-world-data-barriers-to-accelerate-drug-and-device-approvals 2025-12-16T01:26:49+00:00 hourly 0.9 https://trial.medpath.com/news/spruce-biosciences-adds-commercial-veteran-keli-walbert-to-board-ahead-of-sanfilippo-syndrome-therapy-bla 2025-12-15T21:36:14+00:00 hourly 0.9 https://trial.medpath.com/news/ophidion-and-neuronasal-form-strategic-partnership-to-advance-cns-therapeutics-for-parkinson-s-disease-and-metabolic-disorders 2025-12-15T21:33:22+00:00 hourly 0.9 https://trial.medpath.com/news/cure-rare-disease-secures-7-4-million-cirm-grant-for-novel-gene-therapy-targeting-lgmd2i-r9 2025-12-15T21:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-declines-patent-case-that-could-impact-heart-failure-drug-entresto-and-pharmaceutical-innovation 2025-12-15T21:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/jaguar-health-submits-abstract-for-crofelemer-trial-in-adult-short-bowel-syndrome-patients 2025-12-15T21:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-advances-two-phase-1-trials-targeting-kidney-disease-and-liver-cancer 2025-12-15T21:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/bright-minds-biosciences-raises-175-million-to-advance-epilepsy-drug-bmb-101-through-phase-ii-trials 2025-12-15T21:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-expanded-flibanserin-indication-for-postmenopausal-women-with-hypoactive-sexual-desire-disorder 2025-12-15T21:28:20+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-long-term-efficacy-of-luxturna-gene-therapy-for-inherited-retinal-disease 2025-12-15T19:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/alumis-raises-300-million-in-public-offering-following-planned-acelyrin-merger 2025-12-15T18:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/zenas-biopharma-reports-positive-phase-3-indigo-data-for-obexelimab-in-igg4-related-disease 2025-12-15T17:43:10+00:00 hourly 0.9 https://trial.medpath.com/news/cofactor-genomics-validates-rna-based-biomarker-for-nsclc-immunotherapy-response-in-1400-patient-study 2025-12-15T17:41:21+00:00 hourly 0.9 https://trial.medpath.com/news/pilatus-biosciences-receives-fda-clearance-for-first-in-class-anti-cd36-metabolic-checkpoint-antibody-plt012 2025-12-15T17:38:52+00:00 hourly 0.9 https://trial.medpath.com/news/geovax-s-covid-19-vaccine-shows-superior-t-cell-response-in-cll-patients-prompts-trial-design-change 2025-12-15T17:38:28+00:00 hourly 0.9 https://trial.medpath.com/news/sofie-biosciences-initiates-phase-3-trials-for-18f-fapi-74-pet-tracer-in-gastroesophageal-and-pancreatic-cancers 2025-12-15T17:36:45+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-expands-dren-bio-partnership-with-1-7b-autoimmune-collaboration 2025-12-15T17:36:39+00:00 hourly 0.9 https://trial.medpath.com/news/aviceda-s-avd-104-shows-31-reduction-in-geographic-atrophy-lesion-growth-in-phase-2b-trial 2025-12-15T17:36:17+00:00 hourly 0.9 https://trial.medpath.com/news/noom-launches-microdose-glp-1-program-for-preventive-health-and-longevity 2025-12-15T17:36:14+00:00 hourly 0.9 https://trial.medpath.com/news/ankyra-therapeutics-appoints-sailaja-battula-as-chief-scientific-officer-to-lead-immuno-oncology-pipeline 2025-12-15T17:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/abpro-and-celltrion-submit-ind-application-for-her2-targeting-t-cell-engager-abp-102-ct-p72 2025-12-15T17:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-shows-promise-for-hereditary-spastic-paraplegia-in-preclinical-study 2025-12-15T17:34:58+00:00 hourly 0.9 https://trial.medpath.com/news/algia-pharma-receives-fda-support-for-non-opioid-pain-treatment-algiapak-to-enter-phase-2-trials 2025-12-15T17:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/cgt-catapult-launches-recell-consortium-to-develop-universal-safety-tests-for-cell-therapies 2025-12-15T17:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-roxadustat-for-myelodysplastic-syndromes-treatment 2025-12-15T17:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/immusoft-receives-fda-orphan-drug-designation-for-engineered-b-cell-therapy-isp-002-in-hunter-syndrome 2025-12-15T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/netramark-secures-phase-3-contract-following-fda-milestone-for-ai-powered-clinical-trial-platform 2025-12-15T17:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/cannabis-compounds-cbd-and-thc-show-promise-against-ovarian-cancer-in-laboratory-study 2025-12-15T17:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/adaptive-biotechnologies-partners-with-pfizer-in-890m-tcr-discovery-deal-for-rheumatoid-arthritis 2025-12-15T17:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/chai-discovery-raises-130m-series-b-to-accelerate-ai-driven-drug-discovery-platform 2025-12-15T17:30:50+00:00 hourly 0.9 https://trial.medpath.com/news/rona-therapeutics-completes-first-cohort-of-phase-1-trial-for-novel-inhbe-targeting-sirna-obesity-treatment 2025-12-15T17:30:16+00:00 hourly 0.9 https://trial.medpath.com/news/actuate-therapeutics-reports-positive-phase-ii-results-for-elraglusib-in-advanced-salivary-gland-cancers 2025-12-15T17:29:40+00:00 hourly 0.9 https://trial.medpath.com/news/dyadic-applied-biosolutions-expands-strategic-partnerships-to-accelerate-commercial-growth-of-recombinant-protein-portfolio 2025-12-15T17:29:38+00:00 hourly 0.9 https://trial.medpath.com/news/pixelgen-technologies-expands-protein-interactomics-platform-to-south-korea-through-strategic-distribution-partnership 2025-12-15T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/china-medical-system-s-jak1-inhibitor-povorcitinib-receives-breakthrough-therapy-designation-for-vitiligo-treatment 2025-12-15T17:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/kenai-therapeutics-initiates-first-in-human-trial-of-rndp-001-neuron-replacement-therapy-for-parkinson-s-disease 2025-12-15T17:28:31+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-completes-phase-2-enrollment-for-novel-microneedle-basal-cell-carcinoma-treatment 2025-12-15T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-posterior-motion-preserving-spinal-device-for-degenerative-disc-disease 2025-12-15T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-nephrodite-s-holly-implantable-dialysis-system 2025-12-15T17:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-s-opaganib-shows-promise-in-overcoming-venetoclax-resistance-in-chronic-lymphocytic-leukemia 2025-12-15T17:27:33+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-submits-bla-for-imsidolimab-to-treat-rare-generalized-pustular-psoriasis 2025-12-15T17:27:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-lerodalcibep-liga-lerochol-as-third-generation-pcsk9-inhibitor-for-cholesterol-management 2025-12-15T17:27:18+00:00 hourly 0.9 https://trial.medpath.com/news/link-cell-therapies-emerges-from-stealth-with-60m-series-a-to-advance-logic-gated-car-t-platform 2025-12-15T17:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/pharmanovia-launches-first-in-class-korjuny-catumaxomab-in-germany-for-malignant-ascites-treatment 2025-12-15T17:26:44+00:00 hourly 0.9 https://trial.medpath.com/news/kyongbo-pharmaceutical-opens-korea-s-first-end-to-end-adc-cdmo-center 2025-12-15T14:42:59+00:00 hourly 0.9 https://trial.medpath.com/news/novel-mrna-lnp-platform-delivers-liver-targeted-t-cell-engager-for-hepatocellular-carcinoma-treatment 2025-12-15T14:42:17+00:00 hourly 0.9 https://trial.medpath.com/news/macro-trial-challenges-long-standing-chronic-rhinosinusitis-treatment-paradigms 2025-12-15T14:41:31+00:00 hourly 0.9 https://trial.medpath.com/news/biovica-secures-commercial-agreement-with-leading-nci-cancer-center-for-divitum-tka-biomarker-test 2025-12-15T14:41:16+00:00 hourly 0.9 https://trial.medpath.com/news/novadip-initiates-pivotal-phase-3-trial-of-nvd003-for-rare-pediatric-bone-condition 2025-12-15T14:41:11+00:00 hourly 0.9 https://trial.medpath.com/news/atelerix-and-cherry-biotech-partner-to-enable-global-shipping-of-organoid-models-using-hydrogel-preservation-technology 2025-12-15T14:40:31+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-gains-fda-priority-review-for-opdivo-in-hodgkin-lymphoma 2025-12-15T14:40:22+00:00 hourly 0.9 https://trial.medpath.com/news/amphastar-receives-fda-approval-for-generic-teriparatide-injection-challenging-eli-lilly-s-forteo-in-585m-osteoporosis-market 2025-12-15T14:40:20+00:00 hourly 0.9 https://trial.medpath.com/news/ausperbio-completes-phase-iii-enrollment-for-ahb-137-hepatitis-b-therapy-following-30-functional-cure-rate 2025-12-15T14:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/believer-meats-ceases-operations-despite-achieving-fda-and-usda-regulatory-approvals-for-cultivated-chicken 2025-12-15T14:38:11+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-drug-screen-reveals-common-medicines-can-enhance-crispr-therapy-and-target-dna-repair-deficient-cancers 2025-12-15T14:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/akums-launches-enhanced-gabapentin-er-tablets-with-retenex-technology-for-postherpetic-neuralgia-management 2025-12-15T14:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/minghui-pharmaceutical-receives-fda-clearance-for-phase-iii-trials-of-novel-thyroid-eye-disease-treatment 2025-12-15T14:36:24+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-trial-death-raises-safety-concerns-for-brain-targeted-aav-treatments 2025-12-15T14:35:33+00:00 hourly 0.9 https://trial.medpath.com/news/enveric-biosciences-raises-3-1-million-through-warrant-exercise-to-advance-neuroplastogenic-therapeutics 2025-12-15T09:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/argenx-discontinues-phase-3-uplighted-studies-of-efgartigimod-sc-in-thyroid-eye-disease-following-futility-analysis 2025-12-15T09:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/gc-biopharma-selected-for-korea-s-covid-19-mrna-vaccine-phase-1-clinical-trial-support-program 2025-12-15T09:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-tolebrutinib-fails-phase-3-trial-in-primary-progressive-multiple-sclerosis 2025-12-15T09:30:21+00:00 hourly 0.9 https://trial.medpath.com/news/prescient-therapeutics-receives-european-approval-for-ptx-100-phase-2a-trial-in-rare-t-cell-lymphoma 2025-12-15T09:30:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-crispr-cas13-rna-editing-trial-for-wet-age-related-macular-degeneration 2025-12-15T09:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/kaist-researchers-develop-ai-engineered-interferon-lambda-nasal-spray-for-broad-spectrum-respiratory-virus-protection 2025-12-15T09:28:59+00:00 hourly 0.9 https://trial.medpath.com/news/dimerix-completes-recruitment-for-phase-3-trial-of-dmx-200-in-rare-kidney-disease-fsgs 2025-12-15T09:27:46+00:00 hourly 0.9 https://trial.medpath.com/news/indupro-therapeutics-secures-strategic-investment-from-sanofi-for-novel-bispecific-pd-1-agonist-program 2025-12-15T09:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/china-mandates-rigorous-clinical-trials-for-traditional-medicine-injections-in-historic-regulatory-overhaul 2025-12-15T09:26:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-faces-growing-dilemma-as-10-of-approved-drugs-fail-primary-endpoints-in-pivotal-trials 2025-12-15T09:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-launches-glp-1-liraglutide-in-netherlands-marking-first-eu-direct-brand-launch 2025-12-15T09:26:09+00:00 hourly 0.9 https://trial.medpath.com/news/cynata-therapeutics-completes-enrollment-in-phase-2-trial-of-cyp-001-for-acute-graft-versus-host-disease 2025-12-15T05:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/immunome-prepares-to-release-phase-3-ringside-trial-results-for-varegacestat-in-desmoid-tumors 2025-12-15T01:27:20+00:00 hourly 0.9 https://trial.medpath.com/news/hyperfine-initiates-clinical-study-to-expand-portable-mri-capabilities-with-contrast-enhancement 2025-12-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cencora-expands-rare-disease-services-through-strategic-partnership-with-curant-health 2025-12-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/kyverna-therapeutics-to-report-phase-2-trial-results-for-car-t-cell-therapy-in-stiff-person-syndrome 2025-12-14T21:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/allegria-therapeutics-raises-5-1-million-to-advance-mast-cell-targeted-therapies-for-allergic-diseases 2025-12-14T21:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/bioretec-receives-fda-breakthrough-device-designation-for-biodegradable-remeos-drillpin 2025-12-14T21:30:34+00:00 hourly 0.9 https://trial.medpath.com/news/vaxcyte-initiates-phase-3-opus-trial-for-vax-31-pneumococcal-vaccine-with-strong-institutional-backing 2025-12-14T17:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/forskolin-shows-dual-mechanism-against-aggressive-kmt2a-rearranged-acute-myeloid-leukemia 2025-12-14T17:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/vaxxas-secures-tga-manufacturing-license-for-revolutionary-microarray-patch-vaccine-technology 2025-12-14T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-discovery-identifies-novel-monkeypox-virus-drug-target-opg153 2025-12-14T13:28:02+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-trial-shows-promise-for-glp-1-receptor-agonists-in-large-vessel-occlusion-stroke-treatment 2025-12-14T13:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/novel-lrba-targeting-approach-enhances-cancer-immunotherapy-by-inducing-ctla-4-degradation 2025-12-14T09:28:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-mandated-to-streamline-prescription-to-otc-drug-switch-process-under-new-congressional-legislation 2025-12-14T01:28:22+00:00 hourly 0.9 https://trial.medpath.com/news/theralase-completes-enrollment-of-90-patients-in-phase-ii-bladder-cancer-study-for-light-activated-ruvidar 2025-12-13T21:30:04+00:00 hourly 0.9 https://trial.medpath.com/news/d3-bio-raises-108-million-series-b-to-advance-global-phase-iii-trials-for-kras-g12c-inhibitor-elisrasib 2025-12-13T21:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/schizophrenia-drug-pipeline-surges-with-60-therapies-from-55-companies-as-novel-mechanisms-enter-late-stage-development 2025-12-13T21:27:58+00:00 hourly 0.9 https://trial.medpath.com/news/sobi-acquires-arthrosi-therapeutics-for-950m-to-advance-next-generation-gout-treatment 2025-12-13T21:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-prepares-major-clinical-trial-reform-to-accelerate-drug-approvals-through-single-pivotal-studies 2025-12-13T21:26:48+00:00 hourly 0.9 https://trial.medpath.com/news/quebec-and-netherlands-reject-public-coverage-of-alzheimer-s-drug-lecanemab-despite-health-canada-approval 2025-12-13T21:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/multi-component-intranasal-covid-19-vaccine-shows-promise-in-preclinical-and-early-human-studies 2025-12-13T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/nurexone-advances-exopten-manufacturing-for-first-in-human-studies-in-spinal-cord-and-optic-nerve-injuries 2025-12-13T14:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-secures-global-settlement-for-aflibercept-biosimilar-enabling-worldwide-commercialization 2025-12-13T14:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/aiims-delhi-completes-india-s-first-brain-stent-clinical-trial-achieves-regulatory-approval-for-stroke-treatment 2025-12-13T09:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/radiomedix-secures-5-year-thorium-228-supply-deal-to-advance-targeted-alpha-therapy-pipeline 2025-12-13T09:27:31+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-arpi-data-reinforces-survival-benefits-in-metastatic-prostate-cancer-while-real-world-evidence-gaps-persist 2025-12-13T09:27:06+00:00 hourly 0.9 https://trial.medpath.com/news/sereneuro-s-sn101-pain-sponge-therapy-shows-promise-for-non-opioid-osteoarthritis-treatment 2025-12-13T09:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/anixa-biosciences-breast-cancer-vaccine-shows-74-immune-response-rate-in-phase-1-trial 2025-12-13T05:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/eu-drugs-regulator-backs-higher-dose-of-novo-nordisk-s-wegovy-for-weight-management 2025-12-13T05:27:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-cardamyst-nasal-spray-as-first-self-administered-treatment-for-psvt-in-over-30-years 2025-12-13T05:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/tiziana-life-sciences-initiates-phase-2-trial-testing-intranasal-foralumab-for-alzheimer-s-disease-neuroinflammation 2025-12-13T01:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/alphyn-biologics-raises-25m-series-b-to-advance-zabalafin-hydrogel-through-phase-iib-trials-for-atopic-dermatitis 2025-12-13T01:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/zelluna-achieves-manufacturing-milestone-for-first-in-class-mage-a4-tcr-nk-cell-therapy 2025-12-13T01:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-using-ctdna-identifies-colon-cancer-patients-who-benefit-from-celecoxib-anti-inflammatory-therapy 2025-12-13T01:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/edesa-biotech-advances-eb06-anti-cxcl10-antibody-toward-phase-2-vitiligo-trial-in-mid-2026 2025-12-13T01:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/canada-s-drug-agency-reports-10-rise-in-drug-submissions-despite-15-drop-in-approvals-for-2024 2025-12-13T01:26:34+00:00 hourly 0.9 https://trial.medpath.com/news/circulating-tumor-dna-emerges-as-powerful-prognostic-tool-for-triple-negative-breast-cancer-recurrence-risk 2025-12-12T21:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/mineralys-therapeutics-lorundrostat-trial-recognized-in-jama-s-inaugural-research-of-the-year-for-treatment-resistant-hypertension 2025-12-12T21:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/tenaya-therapeutics-reports-positive-gene-therapy-data-for-rare-heart-disease-despite-stock-decline-following-60m-offering 2025-12-12T21:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/relay-therapeutics-zovegalisib-shows-consistent-efficacy-across-breast-cancer-patient-subgroups-in-sabcs-analysis 2025-12-12T21:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/uc-irvine-receives-12-million-grant-for-first-in-human-huntington-s-disease-stem-cell-trial 2025-12-12T21:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/vutrisiran-demonstrates-consistent-cardiovascular-benefits-across-all-age-groups-in-attr-cm-patients 2025-12-12T21:30:45+00:00 hourly 0.9 https://trial.medpath.com/news/sms-pharmaceuticals-passes-usfda-inspection-at-vizag-api-facility-with-minor-observation 2025-12-12T21:30:34+00:00 hourly 0.9 https://trial.medpath.com/news/parse-biosciences-partners-with-tahoe-therapeutics-and-codebreaker-labs-for-massive-single-cell-sequencing-projects 2025-12-12T21:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/arcus-and-gilead-discontinue-tigit-therapy-after-phase-iii-gastric-cancer-trial-failure 2025-12-12T21:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-conditional-approval-for-immunitybio-s-anktiva-in-bcg-unresponsive-bladder-cancer 2025-12-12T21:28:02+00:00 hourly 0.9 https://trial.medpath.com/news/nimacimab-plus-semaglutide-achieves-superior-weight-loss-in-phase-2a-trial 2025-12-12T17:38:48+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-awaits-pivotal-inz-701-trial-results-following-270m-inozyme-acquisition 2025-12-12T17:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-loses-key-patent-protection-for-cancer-drug-cabazitaxel-at-european-court 2025-12-12T17:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/sanyou-bio-and-kanrybio-form-strategic-partnership-to-advance-biomarker-assay-kit-development 2025-12-12T17:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-sector-sees-record-3-5-billion-fundraising-surge-following-ash-conference 2025-12-12T17:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/neuexcell-s-gene-therapy-nxl-004-shows-promising-results-in-first-in-human-trial-for-recurrent-malignant-glioma 2025-12-12T17:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/apremilast-demonstrates-sustained-efficacy-in-moderate-to-severe-genital-psoriasis-through-32-weeks 2025-12-12T17:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/ractigen-therapeutics-initiates-first-in-human-trial-of-rag-18-for-duchenne-muscular-dystrophy 2025-12-12T17:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/peijia-medical-receives-nmpa-approval-for-taurustrio-transcatheter-aortic-valve-system-for-aortic-regurgitation-treatment 2025-12-12T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-committee-recommends-expanding-gsk-s-rsv-vaccine-to-all-adults-18-and-over 2025-12-12T17:30:52+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drugs-show-16-reduction-in-epilepsy-risk-among-diabetes-patients-in-large-scale-study 2025-12-12T17:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-partners-with-taigen-for-ai-driven-anemia-treatment-in-greater-china 2025-12-12T17:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/ema-approves-seven-new-medicines-including-covid-19-vaccine-and-cancer-treatments 2025-12-12T17:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/cytokinetics-receives-positive-european-regulatory-opinion-for-myqorzo-in-obstructive-hypertrophic-cardiomyopathy 2025-12-12T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/csir-and-promptbio-partner-to-advance-ai-driven-precision-medicine-for-african-populations 2025-12-12T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/emergent-biosolutions-secures-fda-approval-for-raxibacumab-manufacturing-at-winnipeg-facility 2025-12-12T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-new-powder-formulation-of-trofinetide-for-enhanced-rett-syndrome-treatment-flexibility 2025-12-12T17:27:30+00:00 hourly 0.9 https://trial.medpath.com/news/suven-life-sciences-completes-phase-2b-enrollment-for-novel-depression-drug-ropanicant-two-months-ahead-of-schedule 2025-12-12T17:27:27+00:00 hourly 0.9 https://trial.medpath.com/news/mass-general-brigham-spins-out-aiwithcare-to-revolutionize-clinical-trial-patient-matching-with-ai 2025-12-12T17:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/acupuncture-shows-promise-for-treating-cognitive-impairment-in-breast-cancer-survivors 2025-12-12T17:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-plans-black-box-warning-for-covid-19-vaccines-amid-safety-concerns 2025-12-12T13:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/uk-and-singapore-launch-first-of-its-kind-regulatory-innovation-corridor-to-accelerate-breakthrough-health-technologies 2025-12-12T13:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/zepbound-weight-loss-drug-enters-clinical-testing-for-long-covid-treatment 2025-12-12T13:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-plans-black-box-warning-for-covid-19-vaccines-amid-scientific-controversy 2025-12-12T13:28:05+00:00 hourly 0.9 https://trial.medpath.com/news/elicio-therapeutics-eli-002-7p-demonstrates-antigen-spreading-in-87-of-phase-2-patients 2025-12-12T13:27:24+00:00 hourly 0.9 https://trial.medpath.com/news/taysha-gene-therapies-advances-tsha-102-to-phase-3-development-for-rett-syndrome-treatment 2025-12-12T13:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/medline-completes-6-26-billion-ipo-becomes-largest-healthcare-public-offering-of-2025 2025-12-12T13:27:16+00:00 hourly 0.9 https://trial.medpath.com/news/stada-and-bio-thera-s-golimumab-biosimilar-gotenfia-receives-positive-chmp-opinion-for-multiple-autoimmune-conditions 2025-12-12T13:27:11+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-s-autoimmune-biosimilar-avtozma-gains-preferred-status-with-major-u-s-pharmacy-benefit-manager 2025-12-12T13:27:08+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharmaceutical-companies-push-fda-to-decouple-facility-inspections-from-drug-approval-timeline 2025-12-12T13:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/orphalan-acquires-orphelia-pharma-to-strengthen-rare-disease-portfolio-in-pediatric-neurology-and-oncology 2025-12-12T13:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/nyu-abu-dhabi-develops-spheromatrix-platform-to-accelerate-cancer-drug-testing-with-freezable-3d-tumor-models 2025-12-12T13:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/ptc-therapeutics-secures-global-approvals-for-sephience-in-pku-treatment-across-canada-and-japan 2025-12-12T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-reports-strong-q3-2025-performance-with-mnexspike-capturing-24-of-us-covid-vaccine-market 2025-12-12T09:29:18+00:00 hourly 0.9 https://trial.medpath.com/news/south-australia-to-launch-car-t-cell-therapy-service-at-royal-adelaide-hospital-by-mid-2026 2025-12-12T09:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/first-commercial-gene-therapy-for-hemophilia-a-administered-in-michigan-outside-clinical-trials 2025-12-12T09:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-receives-fda-breakthrough-therapy-designation-for-daraxonrasib-in-kras-g12-mutant-pancreatic-cancer 2025-12-12T09:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/republican-led-states-challenge-fda-approval-of-generic-mifepristone-in-federal-lawsuits 2025-12-12T09:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/xofluza-demonstrates-superior-efficacy-over-tamiflu-in-reducing-hospitalizations-and-emergency-department-visits 2025-12-12T09:25:45+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-explores-acquisition-of-french-biotech-abivax-for-ulcerative-colitis-drug 2025-12-12T05:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/proton-therapy-demonstrates-10-survival-advantage-over-traditional-radiation-in-landmark-head-and-neck-cancer-trial 2025-12-12T05:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/aprogen-s-herceptin-biosimilar-ap-063-advances-to-regulatory-approval-without-phase-3-trials 2025-12-12T05:26:04+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-study-shows-covid-19-vaccines-reduce-emergency-visits-in-children-by-up-to-76-amid-fda-safety-investigation 2025-12-12T01:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/tenaya-therapeutics-reports-promising-early-results-for-tn-401-gene-therapy-in-rare-heart-disease 2025-12-12T01:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/cycle-pharmaceuticals-acquires-applied-therapeutics-in-0-088-per-share-deal-to-advance-rare-disease-pipeline 2025-12-12T01:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-s-opdivo-plus-yervoy-receives-positive-reimbursement-recommendation-for-msi-h-dmmr-colorectal-cancer-in-canada 2025-12-12T01:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/anixa-s-alpha-lactalbumin-breast-cancer-vaccine-shows-74-immune-response-rate-in-phase-1-trial 2025-12-12T01:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-tenaya-s-tn-201-gene-therapy-for-genetic-heart-disease 2025-12-12T01:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/belzutifan-shows-sustained-efficacy-in-heavily-pretreated-clear-cell-renal-cell-carcinoma-patients 2025-12-12T01:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/crinetics-initiates-phase-3-trial-of-atumelnant-for-congenital-adrenal-hyperplasia 2025-12-12T01:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/evommune-advances-two-novel-inflammatory-disease-programs-following-172-5m-ipo 2025-12-12T01:28:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-uplizna-as-first-cd19-targeted-b-cell-therapy-for-generalized-myasthenia-gravis 2025-12-12T01:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-juliet-trial-data-shows-car-t-therapy-delivers-durable-survival-in-relapsed-b-cell-lymphoma 2025-12-12T01:26:04+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-s-triple-negative-breast-cancer-vaccine-shows-74-immune-response-rate-in-phase-1-trial 2025-12-12T01:25:48+00:00 hourly 0.9 https://trial.medpath.com/news/geron-projects-strong-2026-revenue-growth-for-rytelo-following-strategic-restructuring 2025-12-11T21:40:05+00:00 hourly 0.9 https://trial.medpath.com/news/basilea-and-phare-bio-partner-to-develop-ai-designed-broad-spectrum-antibiotic 2025-12-11T21:38:45+00:00 hourly 0.9 https://trial.medpath.com/news/beyondspring-s-plinabulin-shows-consistent-survival-benefit-in-egfr-wild-type-nsclc-after-anti-pd-l-1-failure 2025-12-11T21:38:21+00:00 hourly 0.9 https://trial.medpath.com/news/rezolute-s-ersodetug-fails-phase-3-trial-for-congenital-hyperinsulinism-stock-plunges-88 2025-12-11T21:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/accenture-invests-in-ryght-ai-to-accelerate-clinical-trial-execution-through-agentic-ai-platform 2025-12-11T21:37:15+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-s-next-generation-trk-inhibitor-zurletrectinib-receives-nmpa-approval-in-china-for-ntrk-fusion-positive-solid-tumors 2025-12-11T21:37:01+00:00 hourly 0.9 https://trial.medpath.com/news/immunewalk-therapeutics-reports-positive-phase-1-results-for-iw-601-novel-myeloid-cell-inhibitor-for-inflammatory-diseases 2025-12-11T21:36:14+00:00 hourly 0.9 https://trial.medpath.com/news/valinor-secures-13-million-seed-funding-to-advance-ai-driven-patient-selection-platform-for-clinical-trials 2025-12-11T21:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/less-invasive-axillary-staging-procedures-show-noninferiority-to-standard-lymph-node-dissection-in-breast-cancer 2025-12-11T21:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/intensity-therapeutics-reports-improved-safety-profile-for-int230-6-in-triple-negative-breast-cancer-trial 2025-12-11T21:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/roswell-park-researchers-develop-il-36-gamma-armored-car-t-cells-to-eradicate-solid-tumors 2025-12-11T21:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/two-novel-therapies-show-promise-for-neovascular-amd-duravyu-insert-and-ixo-vec-gene-therapy-demonstrate-safety-and-efficacy-in-phase-2-trials 2025-12-11T21:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/preoperative-radiation-enhances-immune-response-in-hr-positive-breast-cancer-when-combined-with-pembrolizumab 2025-12-11T21:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/corbus-and-eli-lilly-report-positive-obesity-drug-trial-results-driving-stock-gains 2025-12-11T21:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-announces-771-million-manufacturing-expansion-in-north-carolina-creating-700-jobs 2025-12-11T21:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-cagrisema-falls-short-against-eli-lilly-s-tirzepatide-in-obesity-trial 2025-12-11T21:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/roivant-accelerates-pipeline-timelines-with-multiple-late-stage-programs-advancing-toward-market 2025-12-11T21:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-secures-exclusive-greater-china-rights-to-novel-pcsk9-inhibitor-lerodalcibep 2025-12-11T21:29:38+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-computing-breakthroughs-promise-to-transform-drug-discovery-by-2028 2025-12-11T21:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/ivosidenib-combination-demonstrates-real-world-efficacy-in-idh1-mutated-aml-matching-clinical-trial-results 2025-12-11T21:28:47+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-finds-no-oncologic-benefit-from-routine-preoperative-mri-in-early-stage-breast-cancer 2025-12-11T21:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/baseline-therapeutics-launches-with-novel-glp-1-approach-for-substance-use-disorders 2025-12-11T21:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/tivic-health-acquires-manufacturing-assets-to-accelerate-entolimod-development-with-90m-financing-package 2025-12-11T17:44:31+00:00 hourly 0.9 https://trial.medpath.com/news/avenzo-s-cdk2-inhibitor-avzo-021-shows-promising-activity-in-breast-and-ovarian-cancer-patients 2025-12-11T17:43:29+00:00 hourly 0.9 https://trial.medpath.com/news/renovorx-presents-promising-pharmacokinetic-data-for-tamp-therapy-platform-at-asco-gi-2026 2025-12-11T17:42:50+00:00 hourly 0.9 https://trial.medpath.com/news/purple-biotech-s-captn-3-platform-shows-promise-against-treatment-resistant-cancers-with-dual-tri-specific-antibodies 2025-12-11T17:41:25+00:00 hourly 0.9 https://trial.medpath.com/news/tuhura-biosciences-advances-multi-platform-cancer-immunotherapy-pipeline-with-15-6m-financing 2025-12-11T17:38:33+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-nmpa-accepts-nda-for-novel-brain-cytoprotectant-y-3-for-acute-ischemic-stroke-treatment 2025-12-11T17:37:38+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-secures-fda-approval-for-generic-zylet-ophthalmic-suspension-with-cgt-exclusivity 2025-12-11T17:37:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-first-new-sunscreen-active-ingredient-approval-in-25-years-with-bemotrizinol 2025-12-11T17:37:26+00:00 hourly 0.9 https://trial.medpath.com/news/prolynx-raises-70-million-to-develop-extended-release-obesity-drugs-with-monthly-and-quarterly-dosing 2025-12-11T17:37:24+00:00 hourly 0.9 https://trial.medpath.com/news/proteonic-s-2g-unic-technology-licensed-by-ginkgo-bioworks-for-22-2m-barda-funded-anti-filovirus-antibody-manufacturing-project 2025-12-11T17:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/china-advances-ai-driven-drug-development-with-first-phase-3-trial-and-new-platform-launch 2025-12-11T17:37:09+00:00 hourly 0.9 https://trial.medpath.com/news/rezolute-s-phase-3-trial-for-congenital-hyperinsulinism-drug-fails-to-meet-primary-endpoints 2025-12-11T17:37:04+00:00 hourly 0.9 https://trial.medpath.com/news/autobahn-labs-and-astellas-form-strategic-partnership-to-accelerate-academic-drug-discovery 2025-12-11T17:37:01+00:00 hourly 0.9 https://trial.medpath.com/news/eu-reaches-landmark-deal-on-pharmaceutical-legislation-reform-after-three-years-of-negotiations 2025-12-11T17:36:59+00:00 hourly 0.9 https://trial.medpath.com/news/medra-secures-52-million-series-a-to-develop-ai-powered-autonomous-drug-discovery-platform 2025-12-11T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/news/inotiv-partners-with-vugene-to-advance-ai-driven-drug-discovery-through-multi-omics-platform-integration 2025-12-11T17:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/ophirex-advances-varespladib-for-snakebite-treatment-under-fda-animal-rule-pathway 2025-12-11T17:36:28+00:00 hourly 0.9 https://trial.medpath.com/news/cadrenal-therapeutics-acquires-first-in-class-12-lox-inhibitor-vlx-1005-for-heparin-induced-thrombocytopenia-treatment 2025-12-11T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/ataibeckley-secures-key-u-s-patent-for-emp-01-psychedelic-therapy-extending-exclusivity-through-2043 2025-12-11T17:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/enliven-therapeutics-appoints-rick-fair-as-ceo-to-lead-elvn-001-through-phase-3-trial 2025-12-11T17:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/viromissile-initiates-first-in-human-trial-of-idov-immune-oncolytic-virus-therapy-for-advanced-solid-tumors 2025-12-11T17:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/corbus-pharmaceuticals-crb-913-shows-promising-weight-loss-results-in-phase-1a-obesity-trial 2025-12-11T17:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-and-emocog-partner-to-bring-ultra-sensitive-alzheimer-s-blood-testing-to-korea 2025-12-11T17:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/trogenix-secures-95m-series-a-to-advance-trojan-horse-gene-therapy-for-glioblastoma 2025-12-11T17:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/gerosynth-labs-secures-fda-veterinary-approval-for-multi-species-oncology-drug-trials 2025-12-11T17:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/nanology-advances-novel-intratumoral-cisplatin-formulation-for-fatal-pediatric-brain-cancer-dipg 2025-12-11T17:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/sen-jam-pharmaceutical-secures-equity-backed-partnership-for-phase-3-trial-of-first-in-category-hangover-prevention-therapy 2025-12-11T17:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/her2-negative-breast-cancer-pipeline-expands-with-75-therapies-from-70-companies 2025-12-11T17:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/baxter-smart-infusion-pump-emr-integration-reduces-safety-alerts-by-up-to-50-in-real-world-study 2025-12-11T17:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-s-bhv-1510-shows-promising-efficacy-in-phase-1-trial-combining-trop2-adc-with-cemiplimab 2025-12-11T17:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/tempramed-launches-vivi-cap-smart-first-digital-temperature-protection-device-for-insulin-and-glp-1-medications 2025-12-11T17:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-giants-return-to-neuroscience-with-26-6-billion-in-strategic-acquisitions 2025-12-11T17:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/galderma-initiates-phase-ii-trial-of-nemolizumab-for-chronic-pruritus-of-unknown-origin 2025-12-11T17:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/disco-pharmaceuticals-secures-eur36m-seed-financing-and-appoints-new-ceo-to-advance-surfaceome-targeted-cancer-therapies 2025-12-11T17:29:43+00:00 hourly 0.9 https://trial.medpath.com/news/ac-immune-s-alpha-synuclein-immunotherapy-shows-promise-in-slowing-parkinson-s-disease-progression 2025-12-11T17:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-partners-with-trial-library-to-expand-cancer-clinical-trial-access-using-ai-and-genomic-data 2025-12-11T17:28:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-at-home-brain-stimulation-device-for-major-depression-treatment 2025-12-11T17:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/uk-achieves-global-first-patient-recruitment-in-novel-copd-treatment-trial 2025-12-11T17:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/60-degrees-pharmaceuticals-expands-arakoda-sales-strategy-following-positive-commercial-pilot-results 2025-12-11T17:27:30+00:00 hourly 0.9 https://trial.medpath.com/news/transcode-therapeutics-advances-ttx-mc138-to-phase-2a-trial-for-minimal-residual-disease-in-colorectal-cancer 2025-12-11T17:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-in-duchenne-muscular-dystrophy 2025-12-11T17:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/modified-water-vapor-therapy-shows-promise-for-large-volume-benign-prostatic-hyperplasia-treatment 2025-12-11T16:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicines-for-malaria-venture-joins-iicon-consortium-to-accelerate-infectious-disease-drug-discovery 2025-12-11T13:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-develop-novel-cancer-therapy-using-reprogrammed-mast-cells-to-convert-cold-tumors-into-hot-targets 2025-12-11T13:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/mabylon-initiates-first-in-human-trial-of-novel-tri-specific-antibody-my006-for-peanut-allergy-prevention 2025-12-11T13:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-completes-enrollment-in-pivotal-trial-for-darovasertib-combination-in-metastatic-uveal-melanoma 2025-12-11T13:25:30+00:00 hourly 0.9 https://trial.medpath.com/news/bioversys-initiates-phase-3-trial-for-bv100-antibiotic-following-50-mortality-reduction-in-phase-2 2025-12-11T13:25:27+00:00 hourly 0.9 https://trial.medpath.com/news/centessa-pharmaceuticals-advances-orexin-agonist-pipeline-with-leadership-transition-and-promising-clinical-data 2025-12-11T12:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/rhythm-pharmaceuticals-reports-positive-phase-2-results-for-setmelanotide-in-prader-willi-syndrome 2025-12-11T09:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/zealand-pharma-unveils-metabolic-frontier-2030-strategy-with-otr-therapeutics-partnership 2025-12-11T09:26:44+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-secures-chinese-approval-for-two-rare-blood-disorder-therapies-qfitlia-and-cablivi 2025-12-11T09:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/deep-intelligent-pharma-secures-50m-series-d-to-expand-ai-powered-clinical-documentation-platform 2025-12-11T09:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/cell-and-gene-therapy-market-projected-to-reach-105-billion-by-2033-as-clinical-pipeline-expands 2025-12-11T09:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-pharmaceutical-establishes-u-s-partnering-office-to-accelerate-global-open-innovation-strategy 2025-12-11T09:25:28+00:00 hourly 0.9 https://trial.medpath.com/news/pll-therapeutics-advances-gut-targeting-als-therapy-to-phase-ii-after-positive-safety-results 2025-12-11T05:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/heartbeam-receives-fda-clearance-for-first-cable-free-12-lead-ecg-device-for-home-arrhythmia-assessment 2025-12-11T05:27:21+00:00 hourly 0.9 https://trial.medpath.com/news/blood-tests-show-promise-for-personalized-breast-cancer-treatment-selection 2025-12-11T05:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/senator-hawley-challenges-fda-over-alleged-delay-in-mifepristone-safety-review 2025-12-11T05:26:14+00:00 hourly 0.9 https://trial.medpath.com/news/natera-s-signatera-mrd-test-shows-powerful-prognostic-value-in-phase-iii-pallas-breast-cancer-study 2025-12-11T05:25:28+00:00 hourly 0.9 https://trial.medpath.com/news/ro-telehealth-platform-demonstrates-clinical-trial-level-semaglutide-outcomes-in-real-world-study 2025-12-11T05:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/bbot-presents-first-in-class-ras-pi3ka-breaker-bbo-10203-data-at-sabcs-launches-phase-1-trial 2025-12-11T01:33:40+00:00 hourly 0.9 https://trial.medpath.com/news/gri-bio-s-gri-0621-shows-promise-in-phase-2a-ipf-trial-with-disease-modifying-potential 2025-12-11T01:30:14+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-partners-with-nanexa-on-pharmashell-drug-delivery-technology-in-500m-deal 2025-12-11T01:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/aardvark-therapeutics-initiates-international-expansion-of-phase-3-hero-trial-for-prader-willi-syndrome-treatment 2025-12-11T01:28:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expert-panel-calls-for-testosterone-therapy-label-revisions-following-cardiovascular-safety-data 2025-12-11T01:28:22+00:00 hourly 0.9 https://trial.medpath.com/news/lir-life-sciences-advances-needle-free-obesity-treatment-with-novel-transdermal-glp-gip-delivery-platform 2025-12-11T01:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/serina-therapeutics-responds-to-fda-clinical-hold-on-ser-252-parkinson-s-disease-treatment 2025-12-11T01:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/mediwound-s-nexobrid-r-demonstrates-92-5-reduction-in-traumatic-tattoos-from-blast-and-abrasion-injuries 2025-12-11T01:26:36+00:00 hourly 0.9 https://trial.medpath.com/news/karyopharm-prepares-for-pivotal-2026-with-phase-3-myelofibrosis-data-expected-in-march 2025-12-11T01:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-multimodal-models-show-superior-breast-cancer-recurrence-risk-prediction-in-tailorx-validation-study 2025-12-11T01:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/medinatura-issues-nationwide-recall-of-reboost-nasal-spray-due-to-life-threatening-microbial-contamination 2025-12-10T21:40:36+00:00 hourly 0.9 https://trial.medpath.com/news/carrick-therapeutics-reports-promising-phase-2-results-for-cdk7-inhibitor-samuraciclib-in-advanced-breast-cancer 2025-12-10T21:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-tempo-digital-health-pilot-to-accelerate-access-to-chronic-disease-management-technologies 2025-12-10T21:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/fibrobiologics-files-patent-for-novel-fibroblast-based-chondrocyte-spheroid-platform-targeting-orthopedic-conditions 2025-12-10T21:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-reports-100-procedural-success-in-atrial-fibrillation-study-and-durable-remissions-in-multiple-myeloma-trial 2025-12-10T21:36:16+00:00 hourly 0.9 https://trial.medpath.com/news/romosozumab-demonstrates-superior-fracture-reduction-compared-to-pth-analogs-in-real-world-study 2025-12-10T21:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/trispecific-antibody-shows-promise-for-immunotherapy-resistant-tumors-through-multi-target-approach 2025-12-10T21:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/indivumed-partners-with-university-of-rochester-to-accelerate-precision-cancer-therapeutic-discovery 2025-12-10T21:33:25+00:00 hourly 0.9 https://trial.medpath.com/news/bioxodes-secures-eur5-5-million-to-advance-first-in-class-stroke-treatment-toward-pivotal-trial 2025-12-10T21:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/children-s-health-defense-petitions-fda-to-revoke-covid-19-vaccine-licenses-over-regulatory-compliance-concerns 2025-12-10T21:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-fdx2-as-potential-drug-target-for-friedreich-s-ataxia-treatment 2025-12-10T21:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-advances-first-in-class-telomere-targeting-therapy-ateganosine-into-phase-3-for-treatment-resistant-nsclc 2025-12-10T21:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-study-identifies-biological-mechanism-behind-mrna-covid-19-vaccine-associated-myocarditis 2025-12-10T21:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/genfit-s-gns561-combination-therapy-shows-disease-stabilization-in-advanced-cholangiocarcinoma-patients 2025-12-10T21:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/sentynl-therapeutics-partners-with-mytomorrows-to-expand-global-access-to-rare-disease-treatments 2025-12-10T21:26:32+00:00 hourly 0.9 https://trial.medpath.com/news/van-andel-institute-and-cure-parkinson-s-renew-1-5m-annual-funding-for-world-s-largest-parkinson-s-drug-repurposing-initiative 2025-12-10T21:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/curis-secures-20-2-million-funding-to-advance-emavusertib-cancer-pipeline-following-positive-aml-trial-results 2025-12-10T17:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/staar-surgical-shareholders-reject-alcon-s-1-6-billion-acquisition-offer-deal-terminated 2025-12-10T17:37:06+00:00 hourly 0.9 https://trial.medpath.com/news/azura-ophthalmics-receives-positive-fda-feedback-for-first-in-class-dry-eye-treatment-targeting-meibomian-gland-dysfunction 2025-12-10T17:35:42+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-allocates-6-billion-for-strategic-acquisitions-in-internal-medicine-and-immunology-following-metsera-deal 2025-12-10T17:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/psithera-raises-47-5-million-series-a-to-develop-oral-drugs-for-tnf-superfamily-targets 2025-12-10T17:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-scientists-develop-15-minute-hepatitis-c-test-enabling-same-day-treatment 2025-12-10T17:35:17+00:00 hourly 0.9 https://trial.medpath.com/news/dare-bioscience-launches-first-evidence-based-topical-sildenafil-cream-for-women-s-sexual-health 2025-12-10T17:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/russia-completes-first-production-batches-of-personalized-mrna-cancer-vaccine 2025-12-10T17:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-five-novel-lung-cancer-therapies-in-2025-advancing-precision-medicine-and-immunotherapy 2025-12-10T17:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/igyxos-biotherapeutics-reports-positive-phase-1-results-for-igx12-first-in-class-monoclonal-antibody-targeting-male-and-female-infertility 2025-12-10T17:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/bantam-pharmaceutical-initiates-first-in-class-btm-3566-phase-1-trial-for-aggressive-cancers 2025-12-10T17:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/barinthus-bio-s-vtp-1000-shows-promising-safety-and-dose-dependent-effects-in-phase-1-celiac-disease-trial 2025-12-10T17:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/diakonos-oncology-secures-7-million-cprit-grant-to-advance-doc1021-dendritic-cell-therapy-in-refractory-melanoma 2025-12-10T17:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/ventus-therapeutics-doses-first-patient-in-phase-2-trial-of-vent-03-cgas-inhibitor-for-lupus 2025-12-10T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/epilepsygtx-secures-33-million-series-a-to-advance-single-dose-gene-therapy-for-focal-refractory-epilepsy 2025-12-10T17:29:56+00:00 hourly 0.9 https://trial.medpath.com/news/tildrakizumab-demonstrates-sustained-safety-profile-over-four-years-in-psoriatic-arthritis-extension-study 2025-12-10T17:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/ontario-launches-fast-program-with-scemblix-as-first-priority-cancer-therapy-for-cml-patients 2025-12-10T17:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/kazia-s-paxalisib-shows-promise-in-advanced-breast-cancer-with-76-tumor-reduction-and-immune-system-reinvigoration 2025-12-10T17:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/cellenkos-ck0804-regulatory-t-cell-therapy-shows-promise-in-jak-inhibitor-resistant-myelofibrosis 2025-12-10T17:27:43+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-rsi-trial-reveals-etomidate-safer-than-ketamine-for-emergency-intubation 2025-12-10T17:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-submits-ind-for-first-in-class-kat6-7-dual-inhibitor-ide574-targeting-breast-and-lung-cancers 2025-12-10T17:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/allonnia-raises-20-million-to-advance-biotechnology-platform-for-critical-mineral-recovery 2025-12-10T17:26:31+00:00 hourly 0.9 https://trial.medpath.com/news/journey-medical-reports-positive-phase-1-results-for-emrosi-rosacea-treatment-showing-no-impact-on-microbiome 2025-12-10T17:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/nitinotes-initiates-pivotal-ease-trial-for-automated-endoscopic-sleeve-gastroplasty-system 2025-12-10T17:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/trial-library-secures-10-million-series-a-to-democratize-clinical-trial-access-through-ai-enabled-community-platform 2025-12-10T17:24:50+00:00 hourly 0.9 https://trial.medpath.com/news/hemostemix-receives-fda-support-for-basket-protocol-approach-in-stem-cell-therapy-development 2025-12-10T16:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/blossomhill-therapeutics-secures-84-million-to-advance-first-in-class-egfr-inhibitor-for-lung-cancer 2025-12-10T13:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/mmi-achieves-major-milestones-with-fda-clearance-for-robotic-microsurgical-instruments-and-new-cpt-reimbursement-code 2025-12-10T13:37:11+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drugs-show-no-increased-cancer-risk-in-large-meta-analysis-of-94000-patients 2025-12-10T13:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/pharmala-biotech-advances-mdma-manufacturing-and-novel-ala-002-development-for-clinical-trials 2025-12-10T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-biotherapeutics-partners-with-gsk-in-multi-target-cancer-drug-discovery-collaboration 2025-12-10T13:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/physiomics-expands-biometrics-services-with-gardp-partnership-for-antibiotic-trial-optimization 2025-12-10T13:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/cytiva-and-fida-biosystems-partner-to-accelerate-drug-discovery-through-combined-analytical-platform 2025-12-10T13:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/biotechnology-sector-experiences-market-volatility-following-december-2025-clinical-trial-results 2025-12-10T13:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-gene-therapy-for-wiskott-aldrich-syndrome-marking-historic-milestone-for-non-profit-drug-development 2025-12-10T13:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/bendit-technologies-receives-fda-clearance-for-world-s-smallest-steerable-microcatheter 2025-12-10T13:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/vortex-launches-clinical-study-to-transform-cancer-monitoring-with-live-cell-liquid-biopsy-technology 2025-12-10T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/polpharma-biologics-partners-with-libbs-farmaceutica-to-bring-autoimmune-biosimilar-to-brazilian-market 2025-12-10T09:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-gsk-s-b7-h3-targeted-adc-for-small-cell-lung-cancer 2025-12-10T09:25:29+00:00 hourly 0.9 https://trial.medpath.com/news/lunai-bioworks-launches-ai-driven-drug-discovery-programs-for-alcohol-use-disorder-and-parkinson-s-disease 2025-12-10T05:29:15+00:00 hourly 0.9 https://trial.medpath.com/news/medicenna-s-mdna11-shows-promising-anti-tumor-activity-in-advanced-solid-tumors-at-esmo-io-congress-2025 2025-12-10T05:28:02+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-researchers-identify-distinct-biomarkers-for-predicting-car-t-cell-therapy-response-in-b-cell-lymphoma 2025-12-10T05:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/uspto-introduces-subject-matter-eligibility-declarations-to-streamline-patent-protection-for-life-sciences-innovations 2025-12-10T05:27:28+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-initiates-first-in-human-trial-of-ibi3011-novel-anti-il-1rap-monoclonal-antibody-for-gout-treatment 2025-12-10T05:26:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reverses-course-on-nmn-reinstates-dietary-supplement-status-after-legal-challenge 2025-12-10T05:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-gene-therapy-for-wiskott-aldrich-syndrome 2025-12-10T05:26:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-provee-system-first-next-generation-prostatic-urethral-stent-for-benign-prostatic-hyperplasia 2025-12-10T05:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/akari-therapeutics-reports-promising-preclinical-data-for-aktx-101-in-k-ras-mutant-pancreatic-cancer 2025-12-10T03:21:37+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-adds-duchenne-muscular-dystrophy-to-newborn-screening-panel-boosting-sarepta-s-market-prospects 2025-12-10T03:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-launches-integrated-drug-development-platform-to-address-industry-fragmentation 2025-12-10T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-adrabetadex-for-infantile-onset-niemann-pick-disease-type-c 2025-12-10T00:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/idorsia-s-dual-orexin-receptor-antagonist-wins-inaugural-prix-galien-bridges-award-for-insomnia-treatment-innovation 2025-12-10T00:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-announces-6-billion-alabama-manufacturing-facility-for-glp-1-and-small-molecule-medicines 2025-12-10T00:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/hothouse-therapeutics-emerges-with-ps2-9m-to-revolutionize-plant-based-drug-manufacturing-using-ai 2025-12-10T00:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/magnus-medical-enrolls-first-patient-in-11-6m-dod-funded-trial-of-saint-therapy-for-postpartum-depression 2025-12-10T00:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/lexicon-pharmaceuticals-advances-multiple-late-stage-programs-with-key-2026-2027-milestones 2025-12-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cardiff-oncology-s-plk1-inhibitor-onvansertib-shows-promise-in-cmml-trial-and-advances-toward-phase-iii-in-colorectal-cancer 2025-12-09T21:39:14+00:00 hourly 0.9 https://trial.medpath.com/news/forensic-review-reveals-undisclosed-deaths-and-data-discrepancies-in-pfizer-covid-19-vaccine-trial 2025-12-09T21:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-biontech-lp-8-1-adapted-covid-19-vaccine-receives-regulatory-approval-in-australia-and-new-zealand 2025-12-09T21:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/dexamethasone-prophylaxis-reduces-severe-neurotoxicity-in-car-t-therapy-without-compromising-efficacy 2025-12-09T21:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/regenerative-patch-technologies-initiates-phase-iib-trial-for-stem-cell-based-retinal-implant-in-geographic-atrophy 2025-12-09T21:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/cytoagents-to-present-cto1681-data-demonstrating-reduced-car-t-toxicity-without-compromising-efficacy-at-esmo-2025 2025-12-09T21:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-and-ai-transform-rare-disease-clinical-trial-design-through-synthetic-control-arms 2025-12-09T21:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-nda-for-trn-257-first-once-nightly-low-sodium-oxybate-for-narcolepsy-and-idiopathic-hypersomnia 2025-12-09T21:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/phanes-therapeutics-to-present-first-clinical-data-for-spevatamig-in-metastatic-pancreatic-cancer-at-asco-gi-2026 2025-12-09T21:29:09+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-researchers-develop-first-small-molecule-inhibitor-for-undruggable-cancer-protein-igf2bp3 2025-12-09T21:28:32+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-enrolls-first-patient-in-pivotal-phase-3-trial-for-abuse-resistant-opioid-pf614 2025-12-09T21:28:07+00:00 hourly 0.9 https://trial.medpath.com/news/celldex-advances-barzolvolimab-into-phase-3-trials-for-cold-urticaria-and-symptomatic-dermographism 2025-12-09T21:28:04+00:00 hourly 0.9 https://trial.medpath.com/news/pds-biotechnology-secures-new-japanese-patent-for-cancer-immunotherapy-pds0101-extending-protection-into-2040s 2025-12-09T21:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/airiver-medical-receives-fda-ide-approval-for-pivotal-trial-of-drug-coated-balloon-in-chronic-rhinosinusitis 2025-12-09T21:27:21+00:00 hourly 0.9 https://trial.medpath.com/news/pulse-biosciences-advances-nanosecond-pulsed-field-ablation-technology-with-fda-approvals-for-cardiac-and-thyroid-cancer-studies 2025-12-09T21:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/new-mexico-accelerates-psilocybin-therapy-program-launch-to-december-2026-new-jersey-approves-hospital-based-pilot 2025-12-09T21:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-first-postpartum-depression-specific-drug-zurzuvae 2025-12-09T21:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/enveda-advances-first-in-class-oral-therapy-env-294-to-phase-2-trials-for-atopic-dermatitis-and-asthma 2025-12-09T21:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-advances-ultrasensitive-mrd-testing-with-march-2026-clinical-launch 2025-12-09T17:42:31+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-secures-2-1-billion-deal-for-yaopharma-s-oral-glp-1-obesity-drug 2025-12-09T17:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/epivax-and-fda-scientists-identify-immunogenicity-risks-in-generic-teriparatide-impurities 2025-12-09T17:41:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-initiates-safety-review-of-infant-rsv-drugs-beyfortus-and-enflonsia-amid-kennedy-administration-scrutiny 2025-12-09T17:39:44+00:00 hourly 0.9 https://trial.medpath.com/news/sonothera-s-ultrasound-gene-therapy-achieves-65-normal-factor-viii-levels-in-hemophilia-a-primate-study 2025-12-09T17:38:02+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-secures-exclusive-rights-to-yaopharma-s-oral-glp-1-agonist-yp05002-in-2-1-billion-deal 2025-12-09T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/news/vincere-cancer-center-launches-clinical-study-for-syantra-s-immune-based-breast-cancer-screening-test 2025-12-09T17:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-narcolepsy-drug-oveporexton-shows-cognitive-benefits-in-phase-2-trial 2025-12-09T17:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/probiogen-partners-with-spica-therapeutics-to-advance-first-in-class-anti-cd163-antibody-st101-for-cancer-immunotherapy 2025-12-09T17:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/phillips-medisize-showcases-advanced-inhaled-drug-delivery-platforms-at-ddl-2025-following-vectura-acquisition 2025-12-09T17:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/verismo-s-novel-kir-car-platform-shows-superior-tumor-control-with-reduced-toxicity-in-preclinical-studies 2025-12-09T17:34:12+00:00 hourly 0.9 https://trial.medpath.com/news/create-medicines-initiates-first-in-class-frontline-hcc-trial-combining-in-vivo-car-therapy-mt-303-with-standard-immunotherapy 2025-12-09T17:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/destiny-ovarian01-phase-3-trial-launches-to-test-enhertu-as-first-line-maintenance-therapy-for-her2-expressing-ovarian-cancer 2025-12-09T17:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/enterprise-therapeutics-etd001-shows-promise-as-novel-inhaled-enac-blocker-for-cystic-fibrosis-treatment 2025-12-09T17:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/xinnate-advances-tcp-25-for-epidermolysis-bullosa-with-fda-ind-approval-and-first-clinical-publication 2025-12-09T17:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/traction-trial-shows-tranexamic-acid-reduces-blood-transfusions-by-31-in-non-cardiac-surgery-without-increasing-clot-risk 2025-12-09T17:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-safety-data-confirms-long-term-tolerability-of-enjaymo-in-cold-agglutinin-disease-patients 2025-12-09T17:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/benchsci-extends-ai-partnership-with-merck-for-preclinical-disease-biology-research 2025-12-09T17:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/actimed-therapeutics-advances-novel-muscle-preserving-therapies-for-cancer-cachexia-and-glp-1-associated-muscle-loss 2025-12-09T17:30:04+00:00 hourly 0.9 https://trial.medpath.com/news/saol-therapeutics-secures-fda-type-a-meeting-to-advance-sl1009-for-rare-pediatric-mitochondrial-disease 2025-12-09T17:28:58+00:00 hourly 0.9 https://trial.medpath.com/news/curis-reports-62-5-undetectable-mrd-rate-in-aml-triplet-therapy-study-at-ash-2025 2025-12-09T17:28:11+00:00 hourly 0.9 https://trial.medpath.com/news/lee-s-pharmaceutical-acquires-staccato-inhalation-technology-platform-in-strategic-deal-with-ucb-partnership 2025-12-09T17:27:32+00:00 hourly 0.9 https://trial.medpath.com/news/moleculin-advances-miracle-phase-3-aml-trial-with-78-enrollment-first-data-readout-expected-q1-2026 2025-12-09T17:27:29+00:00 hourly 0.9